###begin article-title 0
###xml 72 81 72 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 121 122 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 122 124 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">S&#8414;</xref>
Regulation of Postsynaptic RapGAP SPAR by Polo-like Kinase 2 and the SCFbeta-TRCP Ubiquitin Ligase in Hippocampal Neurons*Sâƒž
###end article-title 0
###begin p 1
Both authors contributed equally to this work.
###end p 1
###begin p 2
###xml 13 66 13 66 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health Pre-doctoral Fellowship</grant-sponsor>
###xml 66 78 66 78 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">F31 NS054507</grant-num>
Supported by National Institutes of Health Pre-doctoral FellowshipF31 NS054507 (NINDS).
###end p 2
###begin p 3
###xml 274 288 274 288 <email xmlns:xlink="http://www.w3.org/1999/xlink">msheng@mit.edu</email>
 An Investigator of the Howard Hughes Medical Institute. To whom correspondence may be addressed: The Picower Institute for Learning and Memory, MA Institute of Technology, 77 Massachusetts Ave. (46-4303), Cambridge, MA 02139. Tel.: 617-452-3716; Fax: 617-452-3692; E-mail: msheng@mit.edu.
###end p 3
###begin p 4
###xml 183 210 183 210 <email xmlns:xlink="http://www.w3.org/1999/xlink">wade_harper@hms.harvard.edu</email>
 To whom correspondence may be addressed: Dept. of Pathology, Harvard Medical School, 77 Ave. Louis Pasteur, NRB 940, Boston, MA 02115. Tel.: 617-432-6590; Fax: 617-432-6591; E-mail: wade_harper@hms.harvard.edu.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 5
###begin p 6
 applies to Author Choice Articles
###end p 6
###begin p 7
###xml 180 189 180 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 365 374 362 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 516 525 510 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 614 623 605 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
The ubiquitin-proteasome pathway (UPP) regulates synaptic function, but little is known about specific UPP targets and mechanisms in mammalian synapses. We report here that the SCFbeta-TRCP complex, a multisubunit E3 ubiquitin ligase, targets the postsynaptic spine-associated Rap GTPase activating protein (SPAR) for degradation in neurons. SPAR degradation by SCFbeta-TRCP depended on the activity-inducible protein kinase Polo-like kinase 2 (Plk2). In the presence of Plk2, SPAR physically associated with the SCFbeta-TRCP complex through a canonical phosphodegron. In hippocampal neurons, disruption of the SCFbeta-TRCP complex by overexpression of dominant interfering beta-TRCP or Cul1 constructs prevented Plk2-dependent degradation of SPAR. Our results identify a specific E3 ubiquitin ligase that mediates degradation of a key postsynaptic regulator of synaptic morphology and function.
###end p 7
###begin p 8
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 93 86 93 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">AG11085</grant-num>
###xml 98 105 98 105 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">GM54137</grant-num>
###xml 262 275 262 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported, in whole or in part, by National Institutes of Health Grants AG11085 and GM54137 (to J. W. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
The on-line version of this article (available at ) contains supplemental Fig. S1.
###end p 9
###begin p 10
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 10
###begin p 11
###xml 499 500 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 502 503 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 792 793 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn6">5</xref>
###xml 795 796 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 797 798 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
Dendritic spines are tiny, actin-rich, dynamic protrusions radiating from the dendritic shaft of principal neurons and comprise the postsynaptic compartment of most glutamatergic synapses of the mammalian brain. The size and morphology of dendritic spines are correlated with their function. Thus, large mushroom-shaped spines tend to be more stable than small thin spines, contain more alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors, and mediate stronger synaptic connections (1, 2). The morphology of spines, which changes during development and in response to synaptic activity, is influenced by multiple signaling pathways that emanate from postsynaptic glutamate receptors and act upon the actin cytoskeleton and associated proteins in the postsynaptic density (PSD)5 (2-4).
###end p 11
###begin p 12
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 178 179 178 179 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
SPAR (spine-associated Rap GTPase activating protein (GAP)) is a PSD protein that regulates spine morphogenesis and forms a complex with the scaffold protein PSD-95 and N-methyl-d-aspartate-type glutamate receptors (5). Overexpression of SPAR results in enlargement of spine heads, an effect dependent upon the ability of SPAR to rearrange actin and function as a RapGAP. In contrast, dominant-negative SPAR produces long and thin spines (5). SPAR, in turn, is regulated by polo-like kinase 2 (Plk2; also known as serum-inducible serine/threonine kinase (SNK)) (6). Synaptic activity induces Plk2 expression (6-8), leading to degradation of SPAR, a mechanism recently shown to be critical in activity-dependent synaptic scaling (a principal form of homeostatic plasticity) (9, 43).
###end p 12
###begin p 13
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
SPAR turnover depends upon the ubiquitin-proteasome pathway (UPP) since ubiquitinated SPAR accumulates in the presence of active Plk2 when proteasomes are inhibited (6). This necessitates the involvement of at least one E3 ubiquitin (Ub) ligase targeting SPAR. More generally, the UPP is known to play an important role in the activity-dependent turnover of several proteins in the PSD (10), a process that likely involves activity-driven redistribution of proteasomes into spines (11). However, as is the case for many neuronal processes in which the UPP has been implicated, the molecular and regulatory components upstream of the proteasome responsible for targeting the ubiquitination of SPAR and other PSD proteins are unknown.
###end p 13
###begin p 14
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 437 439 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 440 442 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 680 689 663 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 857 866 834 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
Skp1/Cul1/F-box protein (SCF) complexes are one of the best understood E3 Ub-ligases with regard to mechanism of substrate recognition (12, 13). By recruiting substrates to the SCF complex, F-box proteins dramatically increase the specificity and rate of ubiquitin transfer to substrates. The F-box protein beta-TRCP has been shown to target critical signaling proteins for degradation, including IkappaBalpha, beta-catenin, and Cdc25A (14-18). Its function in neurons, however, has remained unexplored. Here, we identifybeta-TRCP as the F-box protein that targets Plk2-phosphorylated SPAR for degradation in neurons. Biochemical studies revealed that SPAR interacted with the SCFbeta-TRCP complex through a canonical beta-TRCP phosphodegron. Induction of Plk2 activity led to SPAR turnover, and this was prevented by dominant negative disruption of the SCFbeta-TRCP complex or point mutations in the phosphodegron of SPAR preventing SPAR from interacting with beta-TRCP.
###end p 14
###begin title 15
EXPERIMENTAL PROCEDURES
###end title 15
###begin p 16
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNA Plasmids</italic>
###xml 103 108 103 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">K108M</sup>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 152 157 152 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 409 417 409 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 713 715 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 768 770 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 805 813 793 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 902 904 890 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 952 954 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 957 959 945 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 968 970 956 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1182 1184 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 1186 1188 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 1190 1192 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 1335 1337 1298 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 56 59 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
DNA Plasmids-Expression plasmids expressing cDNA with a CMV promoter for myc-SPAR, HA-Plk2, and HA-Plk2K108M were previously described (6). pCMV-HA-Plk2D201A was created from pCMV-HA-Plk2 using PCR-based mutagenesis. cDNA for full-length SPAR as well as SPAR fragments were amplified from pGW1-myc-SPAR (5) and cloned into pENTR-6, compatible with the GATEway cloning system (Invitrogen). These were used for in vitro LR clonase reactions into pDEST-53 (for GFP-SPAR) or pDEST-N-myc (for myc-SPAR fragments). Point mutations in the beta-TRCP phosphodegron were generated by PCR-based mutagenesis using pCMV-myc-SPAR or pDEST-myc-Act2 as templates. pCMV-myc-CKIepsilon and pCMV-GSK3beta were previously described (19). F-box proteins previously cloned from cDNA pools (14) were re-cloned into pENTR-6, and in vitro LR clonase reactions were performed with pDEST-27 to generate GST-fused F-box proteins. DNCul1 (residues 1-452) was previously described (14); DNCul3 and DNCul4 were prepared by cloning sequences encoding residues 1-418 of Cul3 and 1-440 of Cul4A into pcDNA3 (Invitrogen), respectively. beta-TRCP1DeltaF, Fbw7DeltaF, and Skp2DeltaF plasmids were previously described (14, 20, 21), and beta-TRCP2DeltaF was a gift from N. Khidekel (MIT). pRetroSuper (pRS)-shbeta-TRCP and control shGFP plasmids were previously published (14).
###end p 16
###begin p 17
###xml 0 62 0 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HEK293T Transfections, Binding, Abundance, and Turnover Assays</italic>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
HEK293T Transfections, Binding, Abundance, and Turnover Assays-HEK293T cells were grown in Dulbecco's modified Eagle's medium + 10% serum and seeded (1 x 106 cells/well of a 6-well dish) 16 h before transfection with Lipofectamine 2000 (Invitrogen). Cells were typically harvested approximately24-30 h post-transfection, except for RNAi experiments where cells were harvested 96 h post-transfection after a 48-h selection with puromycin (1 mug/ml) to enrich for a transfected population. Treatment of transfected cells with cycloheximide (25 mug/ml) began 96 h post-transfection.
###end p 17
###begin p 18
###xml 85 86 85 86 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 106 107 106 107 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 117 118 117 118 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 584 595 <span type="species:ncbi:3704">horseradish</span>
###xml 622 627 <span type="species:ncbi:10090">mouse</span>
###xml 649 655 <span type="species:ncbi:9986">rabbit</span>
For assays examining myc-SPAR abundance and turnover, cell pellets were lysed in 50 mm Tris, pH 7.5, 150 mm NaCl, 1 mm EDTA, 0.5% deoxycholate, 1% Nonidet P-40, 0.1% SDS, and cleared lysates were resolved on 4-12% gradient Tris-glycine SDS-PAGE gels. Resolved proteins were then transferred onto nitrocellulose (250 mA, 2 h) and immunoblotted with c-Myc 9E10 (sc-40, Santa-Cruz), HA F-7 (sc-7392, Santa Cruz), Cdk2 M2 (sc-163, Santa Cruz), beta-TRCP1 (Cell Signaling), Cul1 (71-8700, Invitrogen/Zymed Laboratories Inc.), and Cdc25A Ab-3 (MS-640-P0, NeoMarkers), as indicated. Promega horseradish peroxidase-conjugate anti-mouse IgG (W402B) and anti-rabbit IgG (W401B) were used for secondary detection.
###end p 18
###begin p 19
###xml 124 125 124 125 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 505 506 503 504 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 535 536 533 534 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 544 545 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
For single-cell immunofluorescence RNAi experiments, HEK293T cells were seeded onto 18-mm glass coverslips coated with poly-d-lysine (30 mug/ml) and laminin (2 mug/ml) and transfected at 20-30% confluency using calcium phosphate. Cells were fixed 96 h post-transfection for 10 min at room temperature using 4% paraformaldehyde and 4% sucrose in phosphate-buffered saline, and the GFP-SPAR signal was amplified using anti-GFP (A-11122, Invitrogen) at 1:1000 in GDB buffer (1% gelatin, 5% Triton X-100, 50 mm phosphate buffer, pH 7.4, 2 m NaCl) (6).
###end p 19
###begin p 20
###xml 129 130 129 130 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 150 151 150 151 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 161 162 161 162 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 286 287 285 286 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 322 323 321 322 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 323 324 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Binding and ubiquitination detection assays were performed with cleared whole cell lysates from transfected HEK293T cells in 50 mm Tris, pH 7.5, 150 mm NaCl, 1 mm EDTA, 0.5% deoxycholate, and 1% Nonidet P-40. In the case of ubiquitination detection assays, cells were treated with 25 mum MG-132 before harvesting, and 10 mmN-ethylmaleimide was added to the lysis buffer. GSH-Sepharose or c-Myc 9E10-agarose beads (10 mul per condition) were pre-washed in lysis buffer and incubated with 400 mug of lysate for 2 h at 4 degreesC while rocking. Beads were then washed 3-4 times in lysis buffer, and bound protein was eluded in 2x Laemmli protein loading buffer containing SDS. Both GSH-bound samples and crude extract were resolved on 4-12% gradient SDS-PAGE gels. Myc-bound samples were resolved on 6% Tris-Glycine SDS-PAGE gels. Samples were then transferred from the SDS-PAGE onto nitrocellulose and immunoblotted with anti-Myc, anti-HA, anti-FLAG (F3165, Sigma), or anti-GST (26H1, Cell Signaling), as indicated.
###end p 20
###begin p 21
###xml 0 34 0 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neuron Cultures and Immunostaining</italic>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 430 431 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 474 475 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 130 133 <span type="species:ncbi:10116">rat</span>
###xml 439 445 <span type="species:ncbi:9986">rabbit</span>
Neuron Cultures and Immunostaining-Medium-density dissociated hippocampal cultures were prepared and cultured from E19 Long Evans rat hippocampi as previously described (5). Neurons were transfected at DIV16, "super-infected" at DIV18, and fixed approximately18 h post-infection (DIV19) in 1% paraformaldehyde for 2 min at room temperature followed by -20 degreesC methanol for 10 min. Immunostaining was performed in GDB buffer (6) using rabbit SPAR polyclonal antibodies (5) and anti-FLAG M2 (Sigma).
###end p 21
###begin p 22
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Microscopy and Quantification</italic>
Microscopy and Quantification-Fixed neurons and HEK293T cells were imaged with an LSM510 confocal system (Zeiss). A 40x oil immersion lens was used for confocal microscopy, and each image was comprised of 0.5-mum z-stacks projected into a single plane. SPAR immunostaining analysis was performed with MetaMorph Software and carried out blinded with respect to the experimental conditions. Quantification of SPAR puncta involved subjecting images stained for endogenous SPAR to threshold and was carried out from somatic and proximal dendritic regions from transfected, infected, or transfected plus superinfected cells. All SPAR intensity measurements represent integrated SPAR immunostaining intensity per area and are normalized to neighboring uninfected and untransfected cells.
###end p 22
###begin p 23
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Statistical Analysis</italic>
Statistical Analysis-Statistical Methods are described in the figures legends.
###end p 23
###begin title 24
RESULTS
###end title 24
###begin p 25
###xml 0 66 0 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plk2-dependent SPAR Degradation Requires a Cul1-based E3 Ub-ligase</italic>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
Plk2-dependent SPAR Degradation Requires a Cul1-based E3 Ub-ligase-SPAR turnover in neurons is controlled through the UPP in a manner that requires active Plk2 protein kinase (6). Such regulation is reminiscent of the mechanism employed by most SCF E3 Ub-ligases, where substrate recognition depends upon upstream kinase signaling cascades. A central subunit of the SCF complex is the Cul1 scaffold protein. To explore the idea that SPAR turnover is regulated by an SCF E3 Ub-ligase, we made use of a previously reported dominant-negative version of Cul1 (DNCul1). This C-terminal-truncated protein binds substrates but fails to associate with ubiquitin-charged E2 ubiquitin conjugating enzymes, thereby preventing substrate turnover (14, 19, 22).
###end p 25
###begin p 26
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 73 9 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.</bold>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 302 303 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 384 392 384 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 663 668 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 680 683 668 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 753 759 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 815 825 803 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 865 871 853 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yellow</italic>
###xml 927 928 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 933 934 921 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1154 1162 1142 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 1201 1205 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">untr</italic>
###xml 1250 1251 1236 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1283 1286 1269 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 1288 1289 1274 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1318 1319 1304 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 9 1321 9 1307 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27"><bold>Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.</bold><italic>A-C</italic>, dominant negative Cul1 constructs block Plk2-dependent loss of SPAR in hippocampal neurons. Dissociated rat hippocampal neurons (DIV16) were transfected with dominant negative Cullin plasmids (<italic>B</italic> and <italic>C</italic>) or a control plasmid (<italic>A</italic>) and super-infected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). Neurons were fixed &#8764;18 h post-infection and immunostained for endogenous SPAR and infected Plk2. Transfected cells were identified during image acquisition by the presence of a co-transfected &#8220;fill&#8221; protein (GFP, seen in the first column of images). SPAR (<italic>green</italic>) and Plk2 (<italic>red</italic>) were pseudo-colored for illustrative purposes after image analysis. <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions as integrated immunofluorescence intensity per area in cells transfected with indicated plasmids and/or infected with Plk2 Sindbis virus (<italic>Sin-Plk2</italic>), normalized to nearby untransfected (<italic>untr</italic>) cells. Values represent the mean &#177; S.E., <italic>n</italic> &gt; 17 cells for all conditions, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann-Whitney test (<italic>E</italic>).</p>
###xml 9 1321 9 1307 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27"><bold>Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.</bold><italic>A-C</italic>, dominant negative Cul1 constructs block Plk2-dependent loss of SPAR in hippocampal neurons. Dissociated rat hippocampal neurons (DIV16) were transfected with dominant negative Cullin plasmids (<italic>B</italic> and <italic>C</italic>) or a control plasmid (<italic>A</italic>) and super-infected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). Neurons were fixed &#8764;18 h post-infection and immunostained for endogenous SPAR and infected Plk2. Transfected cells were identified during image acquisition by the presence of a co-transfected &#8220;fill&#8221; protein (GFP, seen in the first column of images). SPAR (<italic>green</italic>) and Plk2 (<italic>red</italic>) were pseudo-colored for illustrative purposes after image analysis. <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions as integrated immunofluorescence intensity per area in cells transfected with indicated plasmids and/or infected with Plk2 Sindbis virus (<italic>Sin-Plk2</italic>), normalized to nearby untransfected (<italic>untr</italic>) cells. Values represent the mean &#177; S.E., <italic>n</italic> &gt; 17 cells for all conditions, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann-Whitney test (<italic>E</italic>).</p></caption>
###xml 1321 1321 1307 1307 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0460854240001"/>
###xml 0 1321 0 1307 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="27"><bold>Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.</bold><italic>A-C</italic>, dominant negative Cul1 constructs block Plk2-dependent loss of SPAR in hippocampal neurons. Dissociated rat hippocampal neurons (DIV16) were transfected with dominant negative Cullin plasmids (<italic>B</italic> and <italic>C</italic>) or a control plasmid (<italic>A</italic>) and super-infected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). Neurons were fixed &#8764;18 h post-infection and immunostained for endogenous SPAR and infected Plk2. Transfected cells were identified during image acquisition by the presence of a co-transfected &#8220;fill&#8221; protein (GFP, seen in the first column of images). SPAR (<italic>green</italic>) and Plk2 (<italic>red</italic>) were pseudo-colored for illustrative purposes after image analysis. <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions as integrated immunofluorescence intensity per area in cells transfected with indicated plasmids and/or infected with Plk2 Sindbis virus (<italic>Sin-Plk2</italic>), normalized to nearby untransfected (<italic>untr</italic>) cells. Values represent the mean &#177; S.E., <italic>n</italic> &gt; 17 cells for all conditions, <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann-Whitney test (<italic>E</italic>).</p></caption><graphic xlink:href="zbc0460854240001"/></fig>
###xml 182 185 <span type="species:ncbi:10116">rat</span>
###xml 369 382 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 1139 1152 <span type="species:ncbi:11034">Sindbis virus</span>
FIGURE 1.Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.A-C, dominant negative Cul1 constructs block Plk2-dependent loss of SPAR in hippocampal neurons. Dissociated rat hippocampal neurons (DIV16) were transfected with dominant negative Cullin plasmids (B and C) or a control plasmid (A) and super-infected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (Sin-Plk2). Neurons were fixed approximately18 h post-infection and immunostained for endogenous SPAR and infected Plk2. Transfected cells were identified during image acquisition by the presence of a co-transfected "fill" protein (GFP, seen in the first column of images). SPAR (green) and Plk2 (red) were pseudo-colored for illustrative purposes after image analysis. Arrows point to cells that are both transfected and infected; arrowheads point to cells that are infected only. Yellow indicates the presence of both SPAR and Plk2 staining. D and E, quantification of SPAR immunostaining in somatic and proximal dendritic regions as integrated immunofluorescence intensity per area in cells transfected with indicated plasmids and/or infected with Plk2 Sindbis virus (Sin-Plk2), normalized to nearby untransfected (untr) cells. Values represent the mean +/- S.E., n > 17 cells for all conditions, ***, p < 0.001, Mann-Whitney test (E).
###end p 26
###begin p 27
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.</bold>
###xml 64 67 64 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 375 383 375 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 654 659 642 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 671 674 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 744 750 732 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 806 816 794 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 856 862 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yellow</italic>
###xml 918 919 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 924 925 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1145 1153 1133 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 1192 1196 1180 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">untr</italic>
###xml 1241 1242 1227 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1274 1277 1260 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 1279 1280 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1309 1310 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 173 176 <span type="species:ncbi:10116">rat</span>
###xml 360 373 <span type="species:ncbi:11034">Sindbis virus</span>
###xml 1130 1143 <span type="species:ncbi:11034">Sindbis virus</span>
Plk2-induced SPAR degradation requires a Cul1-based E3 Ubligase.A-C, dominant negative Cul1 constructs block Plk2-dependent loss of SPAR in hippocampal neurons. Dissociated rat hippocampal neurons (DIV16) were transfected with dominant negative Cullin plasmids (B and C) or a control plasmid (A) and super-infected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (Sin-Plk2). Neurons were fixed approximately18 h post-infection and immunostained for endogenous SPAR and infected Plk2. Transfected cells were identified during image acquisition by the presence of a co-transfected "fill" protein (GFP, seen in the first column of images). SPAR (green) and Plk2 (red) were pseudo-colored for illustrative purposes after image analysis. Arrows point to cells that are both transfected and infected; arrowheads point to cells that are infected only. Yellow indicates the presence of both SPAR and Plk2 staining. D and E, quantification of SPAR immunostaining in somatic and proximal dendritic regions as integrated immunofluorescence intensity per area in cells transfected with indicated plasmids and/or infected with Plk2 Sindbis virus (Sin-Plk2), normalized to nearby untransfected (untr) cells. Values represent the mean +/- S.E., n > 17 cells for all conditions, ***, p < 0.001, Mann-Whitney test (E).
###end p 27
###begin p 28
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 245 246 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 355 357 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 371 374 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 363 374 339 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>A-C</italic></xref>
###xml 510 511 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn7">6</xref>
###xml 127 140 <span type="species:ncbi:11034">Sindbis virus</span>
Cultured hippocampal neurons (16 days in vitro (DIV16)) were transfected with DNCul1 and then super-infected 2 days later with Sindbis virus driving expression of FLAG-tagged Plk2 for approximately18 h to promote degradation of endogenous SPAR (6). We infected at a titer that resulted in approximately10% infection rate of cells already transfected with DNCul1 (Fig. 1, A-C). The option of co-transfecting plasmids driving Plk2 expression was precluded by the low Plk2 expression achievable using this method.6
###end p 28
###begin p 29
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 359 374 359 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>A</italic> and <italic>C</italic></xref>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 426 428 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 582 583 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 576 583 576 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 599 600 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
In the absence of Plk2 infection, transfection of control empty vector (pcDNA3.1) or a control dominant-negative Cullin 3 (DNCul3), which disrupts structurally related but functionally distinct Cul3-based complexes (23), had no effect on endogenous SPAR levels relative to nearby untransfected and uninfected cells as assessed by quantitative immunostaining (Fig. 1, A and C, quantified in D). Uninfected cells overexpressing DNCul1 displayed a trend toward increased SPAR levels compared with nearby untransfected cells, but did not reach statistical significance (p = 0.13; Fig. 1B, quantified in D).
###end p 29
###begin p 30
###xml 113 116 113 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 105 116 105 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>A-C</italic></xref>
###xml 118 128 118 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 363 378 363 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>A</italic> and <italic>C</italic></xref>
###xml 421 431 421 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 535 537 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 607 614 607 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 627 633 627 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 659 665 659 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 722 725 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 563 576 <span type="species:ncbi:11034">Sindbis virus</span>
In Plk2-infected but otherwise untransfected neurons, endogenous SPAR levels were close to undetectable (Fig. 1, A-C, arrowheads; quantified in E), in agreement with our previous findings (6). In Plk2-infected cells that had been previously transfected with control empty vector or DNCul3, SPAR levels fell to the same extent as in cells only infected with Plk2 (Fig. 1, A and C, compare SPAR staining in cells marked by arrowheads (infected) and arrows (transfected and infected); quantified in E). However, in cells transfected with DNCul1, infection with Plk2 Sindbis virus failed to reduce SPAR levels (Fig. 1B, notice the yellow color in cells marked by arrows, indicating the presence of both SPAR (green) and Plk2 (red); quantified in E). Thus, Plk2-driven SPAR degradation in neurons depended upon a Cul1-based SCF complex but not any of the structurally related Cul3-based Ub-ligases.
###end p 30
###begin p 31
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPAR Physically Associates with the SCF</italic>
###xml 39 43 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 43 48 40 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 43 56 40 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> Complex</italic>
###xml 461 463 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 587 588 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 581 588 578 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 590 596 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 681 686 678 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 734 735 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 726 735 723 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>A</italic></xref>
###xml 737 743 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 758 767 755 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 4-6</italic>
###xml 773 783 770 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B, lanes 1</italic>
###xml 788 789 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 980 981 977 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 974 981 971 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 983 993 980 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc-SPAR-P</italic>
###xml 1012 1013 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1018 1019 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1004 1019 1001 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>B</italic> and <italic>C</italic></xref>
###xml 442 447 <span type="species:ncbi:9606">human</span>
SPAR Physically Associates with the SCFbeta-TRCP Complex-To further explore the idea that SPAR turnover is regulated by an SCF E3 Ub-ligase, we established a system in cultured HEK293T cells that recapitulates Plk2-dependent SPAR degradation. This system facilitated biochemical studies that were otherwise limited by the physical properties of dendritic spines and allowed the use of molecular reagents previously developed for study of the human SCF pathway (24). We found that expression of SPAR alone (as an Myc-tagged fusion protein) led to its accumulation in HEK293T cells (Fig. 2A, lane 3). In contrast, co-expression with Plk2 (but not a catalytically inactive mutant Plk2D201A) promoted the degradation of myc-SPAR (Fig. 2, A, lane 2 compared with lanes 4-6, and B, lanes 1 and 2). Co-expression of SPAR with wild type Plk2 correlated with the appearance of a slower mobility form of SPAR (presumably phosphorylated) that is sensitive to Plk2-induced degradation (Fig. 2A, myc-SPAR-P; see also Fig. 2, B and C). Our recapitulation of Plk2-dependent SPAR turnover in HEK293T cells provides a convenient system in which to search for components of the Plk2-dependent degradation pathway.
###end p 31
###begin p 32
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 261 276 261 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, <italic>B</italic> and <italic>E</italic></xref>
###xml 465 467 465 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 4</italic>
###xml 544 546 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
Consistent with the idea that SPAR is a target of one of the SCF complexes, overexpression of dominant-negative Cul1 (DNCul1) in HEK293T stabilized myc-SPAR despite cotransfection of active Plk2 (Fig. 2B, lane 3), in agreement with our findings in neurons (see Fig. 1, B and E). Moreover, these cells accumulated the slower migrating form of myc-SPAR that presumably corresponds to phosphorylated SPAR. In contrast, a dominant-negative form of the related Cullin4 (DNCul4) had no effect on SPAR turnover (lane 4), indicating that the effect of DNCul1 was specific.
###end p 32
###begin p 33
###xml 562 564 562 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 798 799 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 792 799 786 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 801 808 795 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 3</italic>
###xml 813 814 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 1101 1103 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 1297 1302 1267 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">K108M</sup>
###xml 1310 1311 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1304 1311 1274 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1313 1320 1283 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 5</italic>
###xml 1325 1326 1295 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 1399 1402 1369 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 1391 1402 1361 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, <italic>A-C</italic></xref>
###xml 1564 1566 1528 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 1642 1643 1606 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1636 1643 1600 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1645 1655 1609 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 7-22</italic>
###xml 1758 1759 1719 1720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1752 1759 1713 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1761 1771 1722 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 7-11</italic>
F-box proteins serve as substrate receptors in Cul1-based E3s. To uncover candidate F-box proteins for SPAR, we performed a cell-based interaction screen in HEK293T cells between SPAR and a panel of co-expressed GST-tagged F-box proteins. Potential complexes between SPAR and GST-tagged F-box proteins were isolated by incubating cell lysates with GSH-Sepharose beads. Previous studies had indicated that the interaction of F-box proteins with substrates can be detected in tissue culture cells that co-express the F-box protein and substrate in the presence of DNCul1, which blocks substrate degradation (14, 19). Among a panel of F-box proteins individually co-transfected with myc-SPAR and HA-Plk2, we identified an interaction between myc-SPAR and both GST-beta-TRCP1 and GST-beta-TRCP2 (Fig. 2C, lanes 3 and 4). Our ability to assay for endogenous interactions was precluded by the unavailability of suitable antibodies for immunoprecipitation. Although produced from different genes, beta-TRCP1 and beta-TRCP2 are approximately85% identical and are believed to have largely redundant functions (25). Importantly, the binding of beta-TRCP1 and beta-TRCP2 to myc-SPAR required co-transfection of active (wild type (WT)) Plk2 and was undetectable in the presence of catalytically defective Plk2K108M (Fig. 2C, lanes 5 and 6). Together with the Plk2-dependent slower gel mobility of SPAR (Fig. 2, A-C), this suggests that SPAR associates with beta-TRCP in a phosphorylation-dependent manner, as is the case for all other beta-TRCP substrates identified to date (13). SPAR did not associate with any of 16 other F-box proteins tested (Fig. 2C, lanes 7-22), including 5 F-box proteins, which like beta-TRCP, bind substrates through their WD40 repeats (Fig. 2C, lanes 7-11). This indicates a high degree of specificity in the interaction between SPAR and beta-TRCP.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 48 9 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SPAR physically associates with the SCF</bold>
###xml 48 52 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 52 57 49 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 52 66 49 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> complex.</bold>
###xml 66 67 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 157 163 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 190 196 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 290 295 283 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 297 303 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 342 344 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 365 374 357 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 4-6</italic>
###xml 561 562 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 669 677 657 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A/WT</sup>
###xml 711 717 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 730 739 717 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 2-9</italic>
###xml 972 973 958 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1046 1054 1031 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/K108M</sup>
###xml 1075 1077 1059 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1132 1138 1115 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 1198 1208 1180 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 3-22</italic>
###xml 1443 1444 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1534 1536 1516 1518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1560 1566 1542 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 1583 1589 1565 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 1601 1607 1583 1589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 1684 1685 1666 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1826 1834 1804 1812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/D201A</sup>
###xml 1894 1899 1867 1872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1-452</sup>
###xml 2044 2053 2016 2025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lanes 1-4</italic>
###xml 9 2120 9 2092 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>SPAR physically associates with the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A</italic>, Plk2-dependent loss of SPAR. HEK293T cells were transfected with 1 &#956;g of pCMV-HA-Plk2 (<italic>lane 1</italic>), 1 &#956;g of pCMV-myc-SPAR (<italic>lane 3</italic>), or 1 &#956;g of pCMV-myc-SPAR together with either 1 &#956;g of catalytically inactive pCMV-HA-Plk2<sup>D201A</sup> (<italic>lane 2</italic>) or increasing amounts of pCMV-HA-Plk2<sup>WT</sup> (0.3, 1, or 2 &#956;g) (<italic>lanes 4-6</italic>). The total amount of transfected DNA was kept constant among all conditions with use of empty vector. Whole cell lysates were immunoblotted with Myc antibody to assess myc-SPAR levels. <italic>B</italic>, dominant negative versions of Cul1 and &#946;-TRCP stabilize SPAR. pCMV-myc-SPAR (0.5 &#956;g) and pCMV-HA-Plk2<sup>D201A/WT</sup> (1 &#956;g) (catalytically inactive, <italic>lane 1</italic>; wild type, <italic>lanes 2-9</italic>) were co-expressed in HEK293T cells with 2.5 &#956;g of either empty vector, dominant negative Cullins, or dominant negative F-box proteins. Changes in the abundance of myc-SPAR were determined by immunoblotting with anti-Myc antibody. <italic>C</italic>, F-box protein interaction screen. pCMV-myc-SPAR (0.6 &#956;g), pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g), and pCMV-<sup>DN</sup>Cul1 (2 &#956;g) were co-expressed as shown with pCMV-GST (<italic>lane 2</italic>) or the indicated F-box proteins as GST fusions (0.6 &#956;g) (<italic>lanes 3-22</italic>) in HEK293T cells seeded in 6-well plates. After 24 h, cell extracts were used for GSH-Sepharose pull-down assays, and proteins were immunoblotted with anti-GST and anti-Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic>, coimmunoprecipitation of SPAR and Plk2. Extracts of HEK293T cells transfected with pCMV-<sup>DN</sup>Cul1 and pCMV-myc-SPAR (<italic>lane 1</italic>), pCMV-HA-Plk2 (<italic>lane 2</italic>), or both (<italic>lane 3</italic>) were immunoprecipitated using anti-Myc or anti-HA antibodies as indicated. <italic>E</italic>, formation of a SPAR&#183;Plk2&#183;&#946;-TRCP&#183;Cul1 complex with active Plk2. Lysates from cells transfected with pCMV-myc-SPAR (0.5 &#956;g), pCMV-HA-Plk2<sup>WT/D201A</sup> (0.5 &#956;g), pCMV-GST-&#946;-TRCP (0.5 &#956;g), and pCMV-FLAG-Cul1<sup>1-452</sup> (2 &#956;g), as indicated, were incubated with GSH-Sepharose and immunoblotted with anti-Myc, anti-HA, anti-GST, and anti-FLAG antibodies as shown. <italic>Lanes 1-4</italic> show lysates (6% of input of the GSH-Sepharose binding reactions).</p>
###xml 9 2120 9 2092 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>SPAR physically associates with the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A</italic>, Plk2-dependent loss of SPAR. HEK293T cells were transfected with 1 &#956;g of pCMV-HA-Plk2 (<italic>lane 1</italic>), 1 &#956;g of pCMV-myc-SPAR (<italic>lane 3</italic>), or 1 &#956;g of pCMV-myc-SPAR together with either 1 &#956;g of catalytically inactive pCMV-HA-Plk2<sup>D201A</sup> (<italic>lane 2</italic>) or increasing amounts of pCMV-HA-Plk2<sup>WT</sup> (0.3, 1, or 2 &#956;g) (<italic>lanes 4-6</italic>). The total amount of transfected DNA was kept constant among all conditions with use of empty vector. Whole cell lysates were immunoblotted with Myc antibody to assess myc-SPAR levels. <italic>B</italic>, dominant negative versions of Cul1 and &#946;-TRCP stabilize SPAR. pCMV-myc-SPAR (0.5 &#956;g) and pCMV-HA-Plk2<sup>D201A/WT</sup> (1 &#956;g) (catalytically inactive, <italic>lane 1</italic>; wild type, <italic>lanes 2-9</italic>) were co-expressed in HEK293T cells with 2.5 &#956;g of either empty vector, dominant negative Cullins, or dominant negative F-box proteins. Changes in the abundance of myc-SPAR were determined by immunoblotting with anti-Myc antibody. <italic>C</italic>, F-box protein interaction screen. pCMV-myc-SPAR (0.6 &#956;g), pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g), and pCMV-<sup>DN</sup>Cul1 (2 &#956;g) were co-expressed as shown with pCMV-GST (<italic>lane 2</italic>) or the indicated F-box proteins as GST fusions (0.6 &#956;g) (<italic>lanes 3-22</italic>) in HEK293T cells seeded in 6-well plates. After 24 h, cell extracts were used for GSH-Sepharose pull-down assays, and proteins were immunoblotted with anti-GST and anti-Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic>, coimmunoprecipitation of SPAR and Plk2. Extracts of HEK293T cells transfected with pCMV-<sup>DN</sup>Cul1 and pCMV-myc-SPAR (<italic>lane 1</italic>), pCMV-HA-Plk2 (<italic>lane 2</italic>), or both (<italic>lane 3</italic>) were immunoprecipitated using anti-Myc or anti-HA antibodies as indicated. <italic>E</italic>, formation of a SPAR&#183;Plk2&#183;&#946;-TRCP&#183;Cul1 complex with active Plk2. Lysates from cells transfected with pCMV-myc-SPAR (0.5 &#956;g), pCMV-HA-Plk2<sup>WT/D201A</sup> (0.5 &#956;g), pCMV-GST-&#946;-TRCP (0.5 &#956;g), and pCMV-FLAG-Cul1<sup>1-452</sup> (2 &#956;g), as indicated, were incubated with GSH-Sepharose and immunoblotted with anti-Myc, anti-HA, anti-GST, and anti-FLAG antibodies as shown. <italic>Lanes 1-4</italic> show lysates (6% of input of the GSH-Sepharose binding reactions).</p></caption>
###xml 2120 2120 2092 2092 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0460854240002"/>
###xml 0 2120 0 2092 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="35"><bold>SPAR physically associates with the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A</italic>, Plk2-dependent loss of SPAR. HEK293T cells were transfected with 1 &#956;g of pCMV-HA-Plk2 (<italic>lane 1</italic>), 1 &#956;g of pCMV-myc-SPAR (<italic>lane 3</italic>), or 1 &#956;g of pCMV-myc-SPAR together with either 1 &#956;g of catalytically inactive pCMV-HA-Plk2<sup>D201A</sup> (<italic>lane 2</italic>) or increasing amounts of pCMV-HA-Plk2<sup>WT</sup> (0.3, 1, or 2 &#956;g) (<italic>lanes 4-6</italic>). The total amount of transfected DNA was kept constant among all conditions with use of empty vector. Whole cell lysates were immunoblotted with Myc antibody to assess myc-SPAR levels. <italic>B</italic>, dominant negative versions of Cul1 and &#946;-TRCP stabilize SPAR. pCMV-myc-SPAR (0.5 &#956;g) and pCMV-HA-Plk2<sup>D201A/WT</sup> (1 &#956;g) (catalytically inactive, <italic>lane 1</italic>; wild type, <italic>lanes 2-9</italic>) were co-expressed in HEK293T cells with 2.5 &#956;g of either empty vector, dominant negative Cullins, or dominant negative F-box proteins. Changes in the abundance of myc-SPAR were determined by immunoblotting with anti-Myc antibody. <italic>C</italic>, F-box protein interaction screen. pCMV-myc-SPAR (0.6 &#956;g), pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g), and pCMV-<sup>DN</sup>Cul1 (2 &#956;g) were co-expressed as shown with pCMV-GST (<italic>lane 2</italic>) or the indicated F-box proteins as GST fusions (0.6 &#956;g) (<italic>lanes 3-22</italic>) in HEK293T cells seeded in 6-well plates. After 24 h, cell extracts were used for GSH-Sepharose pull-down assays, and proteins were immunoblotted with anti-GST and anti-Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic>, coimmunoprecipitation of SPAR and Plk2. Extracts of HEK293T cells transfected with pCMV-<sup>DN</sup>Cul1 and pCMV-myc-SPAR (<italic>lane 1</italic>), pCMV-HA-Plk2 (<italic>lane 2</italic>), or both (<italic>lane 3</italic>) were immunoprecipitated using anti-Myc or anti-HA antibodies as indicated. <italic>E</italic>, formation of a SPAR&#183;Plk2&#183;&#946;-TRCP&#183;Cul1 complex with active Plk2. Lysates from cells transfected with pCMV-myc-SPAR (0.5 &#956;g), pCMV-HA-Plk2<sup>WT/D201A</sup> (0.5 &#956;g), pCMV-GST-&#946;-TRCP (0.5 &#956;g), and pCMV-FLAG-Cul1<sup>1-452</sup> (2 &#956;g), as indicated, were incubated with GSH-Sepharose and immunoblotted with anti-Myc, anti-HA, anti-GST, and anti-FLAG antibodies as shown. <italic>Lanes 1-4</italic> show lysates (6% of input of the GSH-Sepharose binding reactions).</p></caption><graphic xlink:href="zbc0460854240002"/></fig>
FIGURE 2.SPAR physically associates with the SCFbeta-TRCP complex.A, Plk2-dependent loss of SPAR. HEK293T cells were transfected with 1 mug of pCMV-HA-Plk2 (lane 1), 1 mug of pCMV-myc-SPAR (lane 3), or 1 mug of pCMV-myc-SPAR together with either 1 mug of catalytically inactive pCMV-HA-Plk2D201A (lane 2) or increasing amounts of pCMV-HA-Plk2WT (0.3, 1, or 2 mug) (lanes 4-6). The total amount of transfected DNA was kept constant among all conditions with use of empty vector. Whole cell lysates were immunoblotted with Myc antibody to assess myc-SPAR levels. B, dominant negative versions of Cul1 and beta-TRCP stabilize SPAR. pCMV-myc-SPAR (0.5 mug) and pCMV-HA-Plk2D201A/WT (1 mug) (catalytically inactive, lane 1; wild type, lanes 2-9) were co-expressed in HEK293T cells with 2.5 mug of either empty vector, dominant negative Cullins, or dominant negative F-box proteins. Changes in the abundance of myc-SPAR were determined by immunoblotting with anti-Myc antibody. C, F-box protein interaction screen. pCMV-myc-SPAR (0.6 mug), pCMV-HA-Plk2WT/K108M (0.6 mug), and pCMV-DNCul1 (2 mug) were co-expressed as shown with pCMV-GST (lane 2) or the indicated F-box proteins as GST fusions (0.6 mug) (lanes 3-22) in HEK293T cells seeded in 6-well plates. After 24 h, cell extracts were used for GSH-Sepharose pull-down assays, and proteins were immunoblotted with anti-GST and anti-Myc antibodies. Crude lysates were blotted as an input control. D, coimmunoprecipitation of SPAR and Plk2. Extracts of HEK293T cells transfected with pCMV-DNCul1 and pCMV-myc-SPAR (lane 1), pCMV-HA-Plk2 (lane 2), or both (lane 3) were immunoprecipitated using anti-Myc or anti-HA antibodies as indicated. E, formation of a SPAR.Plk2.beta-TRCP.Cul1 complex with active Plk2. Lysates from cells transfected with pCMV-myc-SPAR (0.5 mug), pCMV-HA-Plk2WT/D201A (0.5 mug), pCMV-GST-beta-TRCP (0.5 mug), and pCMV-FLAG-Cul11-452 (2 mug), as indicated, were incubated with GSH-Sepharose and immunoblotted with anti-Myc, anti-HA, anti-GST, and anti-FLAG antibodies as shown. Lanes 1-4 show lysates (6% of input of the GSH-Sepharose binding reactions).
###end p 34
###begin p 35
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SPAR physically associates with the SCF</bold>
###xml 39 43 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 43 48 40 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 43 57 40 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> complex.</bold>
###xml 57 58 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 148 154 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 181 187 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 281 286 274 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 288 294 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 333 335 326 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT</sup>
###xml 356 365 348 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 4-6</italic>
###xml 552 553 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 660 668 648 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A/WT</sup>
###xml 702 708 689 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 721 730 708 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 2-9</italic>
###xml 963 964 949 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1037 1045 1022 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/K108M</sup>
###xml 1066 1068 1050 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1123 1129 1106 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 1189 1199 1171 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 3-22</italic>
###xml 1434 1435 1416 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1525 1527 1507 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1551 1557 1533 1539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</italic>
###xml 1574 1580 1556 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</italic>
###xml 1592 1598 1574 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</italic>
###xml 1675 1676 1657 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1817 1825 1795 1803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/D201A</sup>
###xml 1885 1890 1858 1863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1-452</sup>
###xml 2035 2044 2007 2016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lanes 1-4</italic>
SPAR physically associates with the SCFbeta-TRCP complex.A, Plk2-dependent loss of SPAR. HEK293T cells were transfected with 1 mug of pCMV-HA-Plk2 (lane 1), 1 mug of pCMV-myc-SPAR (lane 3), or 1 mug of pCMV-myc-SPAR together with either 1 mug of catalytically inactive pCMV-HA-Plk2D201A (lane 2) or increasing amounts of pCMV-HA-Plk2WT (0.3, 1, or 2 mug) (lanes 4-6). The total amount of transfected DNA was kept constant among all conditions with use of empty vector. Whole cell lysates were immunoblotted with Myc antibody to assess myc-SPAR levels. B, dominant negative versions of Cul1 and beta-TRCP stabilize SPAR. pCMV-myc-SPAR (0.5 mug) and pCMV-HA-Plk2D201A/WT (1 mug) (catalytically inactive, lane 1; wild type, lanes 2-9) were co-expressed in HEK293T cells with 2.5 mug of either empty vector, dominant negative Cullins, or dominant negative F-box proteins. Changes in the abundance of myc-SPAR were determined by immunoblotting with anti-Myc antibody. C, F-box protein interaction screen. pCMV-myc-SPAR (0.6 mug), pCMV-HA-Plk2WT/K108M (0.6 mug), and pCMV-DNCul1 (2 mug) were co-expressed as shown with pCMV-GST (lane 2) or the indicated F-box proteins as GST fusions (0.6 mug) (lanes 3-22) in HEK293T cells seeded in 6-well plates. After 24 h, cell extracts were used for GSH-Sepharose pull-down assays, and proteins were immunoblotted with anti-GST and anti-Myc antibodies. Crude lysates were blotted as an input control. D, coimmunoprecipitation of SPAR and Plk2. Extracts of HEK293T cells transfected with pCMV-DNCul1 and pCMV-myc-SPAR (lane 1), pCMV-HA-Plk2 (lane 2), or both (lane 3) were immunoprecipitated using anti-Myc or anti-HA antibodies as indicated. E, formation of a SPAR.Plk2.beta-TRCP.Cul1 complex with active Plk2. Lysates from cells transfected with pCMV-myc-SPAR (0.5 mug), pCMV-HA-Plk2WT/D201A (0.5 mug), pCMV-GST-beta-TRCP (0.5 mug), and pCMV-FLAG-Cul11-452 (2 mug), as indicated, were incubated with GSH-Sepharose and immunoblotted with anti-Myc, anti-HA, anti-GST, and anti-FLAG antibodies as shown. Lanes 1-4 show lysates (6% of input of the GSH-Sepharose binding reactions).
###end p 35
###begin p 36
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 179 181 179 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 187 194 187 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 485 486 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 479 486 473 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 488 495 482 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 6</italic>
###xml 500 501 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">8</italic>
###xml 604 609 592 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1-452</sup>
###xml 610 612 598 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 654 659 642 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 712 713 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 706 713 694 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 715 724 703 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 5-8</italic>
###xml 867 868 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 861 868 849 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 878 885 866 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 2</italic>
###xml 890 891 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 897 898 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 903 904 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">8</italic>
Consistent with previous studies that showed interaction between Plk2 and SPAR (6), we found that Plk2 associated with SPAR in a coimmunoprecipitation assay upon co-expression of DNCul1 (Fig. 2D), further validating our heterologous cell system. Interestingly, we also discovered that the associations of Plk2 and beta-TRCP with SPAR were not mutually exclusive, as we were able to detect a ternary interaction with Plk2 that was not precluded by the beta-TRCP-SPAR interaction (Fig. 2E, lanes 6 and 8). GST-beta-TRCP1 (and GST-beta-TRCP2) associated with SPAR, Plk2, and the N terminus of Cullin 1 (Cul11-452/DNCul1), whereas catalytically inactive Plk2D201A did not support assembly of the full complex (Fig. 2E, lanes 5-8). Moreover, the Plk2-dependent slower mobility form of SPAR was enriched in the complex compared with the faster mobility form of SPAR (Fig. 2E, compare lanes 2 and 4 with 6 and 8).
###end p 36
###begin p 37
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 12 9 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SCF</bold>
###xml 12 16 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 16 21 13 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 16 105 13 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.</bold>
###xml 105 106 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 111 112 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 384 385 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 474 475 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 614 615 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 645 647 637 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">**</sup>
###xml 649 650 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 659 661 651 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 752 755 744 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D/A</sup>
###xml 758 759 750 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 764 765 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 985 988 973 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D/A</italic>
###xml 1381 1388 1363 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel D</italic>
###xml 1448 1455 1430 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel C</italic>
###xml 1654 1657 1635 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHX</italic>
###xml 1719 1720 1700 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1995 1996 1965 1966 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2047 2048 2017 2018 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2048 2049 2018 2019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2174 2176 2144 2146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 2204 2206 2174 2176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP</italic>
###xml 9 2227 9 2197 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><bold>SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.</bold><italic>A</italic> and <italic>B</italic>, depletion of &#946;-TRCP by RNAi protects GFP-SPAR from degradation in individual HEK293T cells. The indicated plasmids were transfected with pCMV-RFP as a co-transfection marker into HEK293T cells. After 96 h, cells were fixed and imaged for GFP-SPAR and RFP expression (<italic>A</italic>) and quantified as the percentage of RFP expressing cells that also expressed GFP-SPAR (<italic>B</italic>). Values represent the mean &#177; S.E. from three independent experiments, derived from analysis of 400 cells per experiment per condition (<italic>n</italic> = 1200 cells per condition). <sup>**</sup>, <italic>p</italic> &lt; 0.01; <italic>NS</italic>, not significant; one-way analysis of variance, compared with control condition (pRSP+Plk2<sup>D/A</sup>). <italic>C</italic> and <italic>D</italic>, depletion of &#946;-TRCP by RNAi stabilizes SPAR abundance and turnover in the presence of Plk2 activity. HEK293T cells were transfected with vectors expressing myc-SPAR (0.5 &#956;g), WT, or catalytically inactive HA-Plk2 (<italic>D/A</italic>) (1 &#956;g), and the indicated shRNA vector carrying a puromycin resistance selection marker (2.5 &#956;g). 36 h post-transfection, cells were incubated with media containing 1 &#956;g/ml puromycin to enrich for shRNA expression. Extracts were subsequently examined by immunoblotting 96 h post-transfection as indicated. Endogenous Cdc25A was probed to control for successful knockdown of &#946;-TRCP. In <italic>panel D</italic>, HEK293T cells were transfected in an identical fashion to <italic>panel C</italic>, except that 24 h post-transfection the transfected cells were split among 5 wells in puromycin-containing media. After 48 h of puromycin selection, cells were treated with 25 &#956;g/ml cycloheximide (<italic>CHX</italic>) and harvested at the indicated times before immunoblotting. <italic>E</italic>, expression of &#946;-TRCP promotes Plk2-mediated SPAR ubiquitination. HEK293T cells were transfected with myc-SPAR (1 &#956;g), His-Ub (1 &#956;g), HA-Plk2 (1.5 &#956;g, wild type or D201A), and GST or GST-&#946;-TRCP (4.5 &#956;g). Twenty hours post-transfection cells were treated with 25 &#956;<sc>m</sc> MG-132 for 5 h and lysed in buffer containing 10 m<sc>m</sc><italic>N</italic>-ethylmaleimide. Myc-SPAR was purified with c-Myc 9E10-agarose, resolved on 6% Tris-glycine SDS-PAGE gel, and immunoblotted (<italic>IB</italic>) with anti-Myc antibodies. <italic>IP</italic>, immunoprecipitates.</p>
###xml 9 2227 9 2197 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><bold>SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.</bold><italic>A</italic> and <italic>B</italic>, depletion of &#946;-TRCP by RNAi protects GFP-SPAR from degradation in individual HEK293T cells. The indicated plasmids were transfected with pCMV-RFP as a co-transfection marker into HEK293T cells. After 96 h, cells were fixed and imaged for GFP-SPAR and RFP expression (<italic>A</italic>) and quantified as the percentage of RFP expressing cells that also expressed GFP-SPAR (<italic>B</italic>). Values represent the mean &#177; S.E. from three independent experiments, derived from analysis of 400 cells per experiment per condition (<italic>n</italic> = 1200 cells per condition). <sup>**</sup>, <italic>p</italic> &lt; 0.01; <italic>NS</italic>, not significant; one-way analysis of variance, compared with control condition (pRSP+Plk2<sup>D/A</sup>). <italic>C</italic> and <italic>D</italic>, depletion of &#946;-TRCP by RNAi stabilizes SPAR abundance and turnover in the presence of Plk2 activity. HEK293T cells were transfected with vectors expressing myc-SPAR (0.5 &#956;g), WT, or catalytically inactive HA-Plk2 (<italic>D/A</italic>) (1 &#956;g), and the indicated shRNA vector carrying a puromycin resistance selection marker (2.5 &#956;g). 36 h post-transfection, cells were incubated with media containing 1 &#956;g/ml puromycin to enrich for shRNA expression. Extracts were subsequently examined by immunoblotting 96 h post-transfection as indicated. Endogenous Cdc25A was probed to control for successful knockdown of &#946;-TRCP. In <italic>panel D</italic>, HEK293T cells were transfected in an identical fashion to <italic>panel C</italic>, except that 24 h post-transfection the transfected cells were split among 5 wells in puromycin-containing media. After 48 h of puromycin selection, cells were treated with 25 &#956;g/ml cycloheximide (<italic>CHX</italic>) and harvested at the indicated times before immunoblotting. <italic>E</italic>, expression of &#946;-TRCP promotes Plk2-mediated SPAR ubiquitination. HEK293T cells were transfected with myc-SPAR (1 &#956;g), His-Ub (1 &#956;g), HA-Plk2 (1.5 &#956;g, wild type or D201A), and GST or GST-&#946;-TRCP (4.5 &#956;g). Twenty hours post-transfection cells were treated with 25 &#956;<sc>m</sc> MG-132 for 5 h and lysed in buffer containing 10 m<sc>m</sc><italic>N</italic>-ethylmaleimide. Myc-SPAR was purified with c-Myc 9E10-agarose, resolved on 6% Tris-glycine SDS-PAGE gel, and immunoblotted (<italic>IB</italic>) with anti-Myc antibodies. <italic>IP</italic>, immunoprecipitates.</p></caption>
###xml 2227 2227 2197 2197 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0460854240003"/>
###xml 0 2227 0 2197 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="38"><bold>SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.</bold><italic>A</italic> and <italic>B</italic>, depletion of &#946;-TRCP by RNAi protects GFP-SPAR from degradation in individual HEK293T cells. The indicated plasmids were transfected with pCMV-RFP as a co-transfection marker into HEK293T cells. After 96 h, cells were fixed and imaged for GFP-SPAR and RFP expression (<italic>A</italic>) and quantified as the percentage of RFP expressing cells that also expressed GFP-SPAR (<italic>B</italic>). Values represent the mean &#177; S.E. from three independent experiments, derived from analysis of 400 cells per experiment per condition (<italic>n</italic> = 1200 cells per condition). <sup>**</sup>, <italic>p</italic> &lt; 0.01; <italic>NS</italic>, not significant; one-way analysis of variance, compared with control condition (pRSP+Plk2<sup>D/A</sup>). <italic>C</italic> and <italic>D</italic>, depletion of &#946;-TRCP by RNAi stabilizes SPAR abundance and turnover in the presence of Plk2 activity. HEK293T cells were transfected with vectors expressing myc-SPAR (0.5 &#956;g), WT, or catalytically inactive HA-Plk2 (<italic>D/A</italic>) (1 &#956;g), and the indicated shRNA vector carrying a puromycin resistance selection marker (2.5 &#956;g). 36 h post-transfection, cells were incubated with media containing 1 &#956;g/ml puromycin to enrich for shRNA expression. Extracts were subsequently examined by immunoblotting 96 h post-transfection as indicated. Endogenous Cdc25A was probed to control for successful knockdown of &#946;-TRCP. In <italic>panel D</italic>, HEK293T cells were transfected in an identical fashion to <italic>panel C</italic>, except that 24 h post-transfection the transfected cells were split among 5 wells in puromycin-containing media. After 48 h of puromycin selection, cells were treated with 25 &#956;g/ml cycloheximide (<italic>CHX</italic>) and harvested at the indicated times before immunoblotting. <italic>E</italic>, expression of &#946;-TRCP promotes Plk2-mediated SPAR ubiquitination. HEK293T cells were transfected with myc-SPAR (1 &#956;g), His-Ub (1 &#956;g), HA-Plk2 (1.5 &#956;g, wild type or D201A), and GST or GST-&#946;-TRCP (4.5 &#956;g). Twenty hours post-transfection cells were treated with 25 &#956;<sc>m</sc> MG-132 for 5 h and lysed in buffer containing 10 m<sc>m</sc><italic>N</italic>-ethylmaleimide. Myc-SPAR was purified with c-Myc 9E10-agarose, resolved on 6% Tris-glycine SDS-PAGE gel, and immunoblotted (<italic>IB</italic>) with anti-Myc antibodies. <italic>IP</italic>, immunoprecipitates.</p></caption><graphic xlink:href="zbc0460854240003"/></fig>
FIGURE 3.SCFbeta-TRCP regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.A and B, depletion of beta-TRCP by RNAi protects GFP-SPAR from degradation in individual HEK293T cells. The indicated plasmids were transfected with pCMV-RFP as a co-transfection marker into HEK293T cells. After 96 h, cells were fixed and imaged for GFP-SPAR and RFP expression (A) and quantified as the percentage of RFP expressing cells that also expressed GFP-SPAR (B). Values represent the mean +/- S.E. from three independent experiments, derived from analysis of 400 cells per experiment per condition (n = 1200 cells per condition). **, p < 0.01; NS, not significant; one-way analysis of variance, compared with control condition (pRSP+Plk2D/A). C and D, depletion of beta-TRCP by RNAi stabilizes SPAR abundance and turnover in the presence of Plk2 activity. HEK293T cells were transfected with vectors expressing myc-SPAR (0.5 mug), WT, or catalytically inactive HA-Plk2 (D/A) (1 mug), and the indicated shRNA vector carrying a puromycin resistance selection marker (2.5 mug). 36 h post-transfection, cells were incubated with media containing 1 mug/ml puromycin to enrich for shRNA expression. Extracts were subsequently examined by immunoblotting 96 h post-transfection as indicated. Endogenous Cdc25A was probed to control for successful knockdown of beta-TRCP. In panel D, HEK293T cells were transfected in an identical fashion to panel C, except that 24 h post-transfection the transfected cells were split among 5 wells in puromycin-containing media. After 48 h of puromycin selection, cells were treated with 25 mug/ml cycloheximide (CHX) and harvested at the indicated times before immunoblotting. E, expression of beta-TRCP promotes Plk2-mediated SPAR ubiquitination. HEK293T cells were transfected with myc-SPAR (1 mug), His-Ub (1 mug), HA-Plk2 (1.5 mug, wild type or D201A), and GST or GST-beta-TRCP (4.5 mug). Twenty hours post-transfection cells were treated with 25 mum MG-132 for 5 h and lysed in buffer containing 10 mmN-ethylmaleimide. Myc-SPAR was purified with c-Myc 9E10-agarose, resolved on 6% Tris-glycine SDS-PAGE gel, and immunoblotted (IB) with anti-Myc antibodies. IP, immunoprecipitates.
###end p 37
###begin p 38
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SCF</bold>
###xml 3 7 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 7 12 4 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 7 96 4 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.</bold>
###xml 96 97 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 102 103 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 375 376 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 465 466 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 605 606 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 636 638 628 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">**</sup>
###xml 640 641 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 650 652 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 743 746 735 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D/A</sup>
###xml 749 750 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 755 756 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 976 979 964 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D/A</italic>
###xml 1372 1379 1354 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel D</italic>
###xml 1439 1446 1421 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel C</italic>
###xml 1645 1648 1626 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHX</italic>
###xml 1710 1711 1691 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1986 1987 1956 1957 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2038 2039 2008 2009 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2039 2040 2009 2010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2165 2167 2135 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IB</italic>
###xml 2195 2197 2165 2167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP</italic>
SCFbeta-TRCP regulates Plk2-dependent SPAR abundance, turnover, and promotes its ubiquitination.A and B, depletion of beta-TRCP by RNAi protects GFP-SPAR from degradation in individual HEK293T cells. The indicated plasmids were transfected with pCMV-RFP as a co-transfection marker into HEK293T cells. After 96 h, cells were fixed and imaged for GFP-SPAR and RFP expression (A) and quantified as the percentage of RFP expressing cells that also expressed GFP-SPAR (B). Values represent the mean +/- S.E. from three independent experiments, derived from analysis of 400 cells per experiment per condition (n = 1200 cells per condition). **, p < 0.01; NS, not significant; one-way analysis of variance, compared with control condition (pRSP+Plk2D/A). C and D, depletion of beta-TRCP by RNAi stabilizes SPAR abundance and turnover in the presence of Plk2 activity. HEK293T cells were transfected with vectors expressing myc-SPAR (0.5 mug), WT, or catalytically inactive HA-Plk2 (D/A) (1 mug), and the indicated shRNA vector carrying a puromycin resistance selection marker (2.5 mug). 36 h post-transfection, cells were incubated with media containing 1 mug/ml puromycin to enrich for shRNA expression. Extracts were subsequently examined by immunoblotting 96 h post-transfection as indicated. Endogenous Cdc25A was probed to control for successful knockdown of beta-TRCP. In panel D, HEK293T cells were transfected in an identical fashion to panel C, except that 24 h post-transfection the transfected cells were split among 5 wells in puromycin-containing media. After 48 h of puromycin selection, cells were treated with 25 mug/ml cycloheximide (CHX) and harvested at the indicated times before immunoblotting. E, expression of beta-TRCP promotes Plk2-mediated SPAR ubiquitination. HEK293T cells were transfected with myc-SPAR (1 mug), His-Ub (1 mug), HA-Plk2 (1.5 mug, wild type or D201A), and GST or GST-beta-TRCP (4.5 mug). Twenty hours post-transfection cells were treated with 25 mum MG-132 for 5 h and lysed in buffer containing 10 mmN-ethylmaleimide. Myc-SPAR was purified with c-Myc 9E10-agarose, resolved on 6% Tris-glycine SDS-PAGE gel, and immunoblotted (IB) with anti-Myc antibodies. IP, immunoprecipitates.
###end p 38
###begin p 39
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCF</italic>
###xml 7 12 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</italic>
###xml 3 12 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;<italic>-TRCP</italic></sup>
###xml 12 81 9 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Regulates SPAR Abundance and Turnover and Promotes Its Ubiquitination</italic>
###xml 112 121 109 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 285 286 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 279 286 263 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 527 529 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 531 533 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 535 537 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 700 701 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 694 701 664 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 703 709 673 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 5</italic>
###xml 952 953 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 946 953 901 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 955 964 910 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 6-9</italic>
SCFbeta-TRCPRegulates SPAR Abundance and Turnover and Promotes Its Ubiquitination-To validate a role for the SCFbeta-TRCP complex in Plk2-dependent SPAR turnover, we next examined SPAR abundance in HEK293T cells after expression of dominant-negative beta-TRCP (beta-TRCPDeltaF) (Fig. 2B). The DeltaF-box construct is unable to assemble with Cul1 due to absence of the F-box motif, but it maintains its ability to interact with substrates of both beta-TRCP1 and -2 and can thereby sequester substrates and block their turnover (14, 21, 24). Expression of beta-TRCPDeltaF resulted in increased levels of SPAR, especially of the slower migrating form of SPAR that is dependent upon Plk2 activity (Fig. 2B, lane 5). In contrast, DeltaF-box dominant-negative versions of other F-box proteins Fbw7alpha/beta/gamma (containing WD40 repeats) and Skp2 (containing leucine-rich repeats) failed to promote an increase in the steady state abundance of SPAR (Fig. 2B, lanes 6-9).
###end p 39
###begin p 40
###xml 345 347 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 349 351 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 353 355 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 626 631 608 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 639 640 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 633 640 615 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 734 735 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 728 735 710 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 826 831 808 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">D201A</sup>
###xml 927 928 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 921 928 903 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 944 945 926 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1093 1094 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1087 1094 1066 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 1110 1111 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1338 1339 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1332 1339 1305 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1448 1455 1421 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 1</italic>
###xml 1460 1461 1433 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1583 1589 1553 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lane 4</italic>
###xml 1680 1689 1647 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 1723 1725 1687 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 1727 1729 1691 1693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 202 207 <span type="species:ncbi:9606">human</span>
To directly examine whether beta-TRCP proteins are required for Plk2-dependent SPAR turnover, we took advantage of a shRNA vector (shbeta-TRCP) that is capable of suppressing protein expression of both human beta-TRCP1 and beta-TRCP2. This hairpin sequence and this particular shRNA vector have been validated for numerous beta-TRCP substrates (14, 19, 26). Cells were transfected with expression constructs for GFP-SPAR and red fluorescent protein (RFP) to mark transfected cells and simultaneously transfected with shbeta-TRCP or control vector (pRSP) in the presence of active Plk2 or a catalytically inactive version, Plk2D201A (Fig. 3A). We subsequently visualized cells for the presence of GFP-SPAR in RFP-positive cells (Fig. 3A). RFP-positive cells expressing Plk2, but not those expressing catalytically inactive Plk2D201A, displayed very low levels of GFP-SPAR in the presence of the control shRNA vector pRSP (Fig. 3A, quantified in B). In contrast, RFP-positive cells transfected with shbeta-TRCP contained high levels of GFP-SPAR despite the co-transfection of active Plk2 (Fig. 3A, quantified in B). Thus, depletion of beta-TRCP by RNAi substantially protected GFP-SPAR from Plk2-dependent degradation. Immunoblotting of transfected cell lysates confirmed that Plk2-induced degradation of myc-SPAR requires beta-TRCP (Fig. 3C). As expected, Plk2 promoted loss of myc-SPAR in cells expressing a control shRNA that targets GFP (shGFP) (lanes 1 and 2). In contrast, myc-SPAR was not efficiently degraded in cells depleted of beta-TRCP despite the presence of active Plk2 (lane 4). Furthermore, depletion of beta-TRCP led to accumulation of Cdc25A, a known target of SCFbeta-TRCP used here as a positive control (14, 18).
###end p 40
###begin p 41
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 20 9 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A candidate</bold>
###xml 24 52 21 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP phosphodegron in SPAR.</bold>
###xml 52 53 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 139 143 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Act1</italic>
###xml 148 152 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Act2</italic>
###xml 198 202 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GKBD</italic>
###xml 369 374 363 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 537 538 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 543 544 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 702 703 690 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 714 715 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 815 823 798 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/K108M</sup>
###xml 838 840 820 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1059 1060 1040 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1065 1066 1046 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1190 1191 1168 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1216 1217 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1228 1230 1206 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1242 1244 1220 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1314 1322 1291 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/D201A</sup>
###xml 1339 1341 1315 1317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1688 1689 1656 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1726 1736 1694 1701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP1</sup>
###xml 1864 1866 1829 1831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 2074 2075 2038 2039 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2373 2383 2334 2341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP1</sup>
###xml 2415 2416 2373 2374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2508 2510 2463 2465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 9 2696 9 2644 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>A candidate</bold>&#946;<bold>-TRCP phosphodegron in SPAR.</bold><italic>A</italic>, schematic representation of SPAR domains and SPAR fragments: actin-binding domains (<italic>Act1</italic> and <italic>Act2</italic>), RapGAP, PDZ, and guanylate kinase binding (<italic>GKBD</italic>) domain. The candidate DSGIDT phosphodegron motif (residues 1304-1309) identified in the Act2 domain of SPAR closely resembles the consensus &#946;-TRCP phosphodegron (<italic>inset</italic>). Boundaries of generated C-terminal fragments of SPAR are depicted; C-1, C-2, and Act2 fragments contain the putative phosphodegron motif, whereas C-3 does not. <italic>B</italic> and <italic>C</italic>, SPAR fragments spanning the &#946;-TRCP phosphodegron bind to &#946;-TRCP. HEK293T cells were transfected with vectors expressing SPAR fragments C-1, C-2, C-3 (<italic>B</italic>) or Act2 (<italic>C</italic>) (0.6 &#956;g) either alone or with pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g). In addition, pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g) and <sup>DN</sup>Cul1 (2 &#956;g) were co-transfected as indicated. After 24 h, cell extracts were used for GSH-Sepharose pulldown assays, and proteins were immunoblotted with Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic> and <italic>E</italic>, phosphodegron-dependent binding to &#946;-TRCP. Constructs expressing point mutations (S1305A, T1309A) in full-length SPAR (<italic>E</italic>) and the Act2 fragment (<italic>D</italic>) (myc-SPAR<sup>AA</sup> or myc-Act2<sup>AA</sup>, 0.6 &#956;g) were transfected into HEK293T cells along with pCMV-HA-Plk2<sup>WT/D201A</sup> (0.6 &#956;g), pCMV-<sup>DN</sup>Cul1 (2 &#956;g), and pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g) as indicated. Cell lysates were incubated with GSH-Sepharose and immunoblotted with Myc antibodies. Crude extracts were resolved to control for input. Wild type constructs expressing myc-SPAR and myc-Act2 were used for comparison as a positive control for interaction with GST-&#946;-TRCP. <italic>F</italic>, SPAR associates with endogenous SCF<sup>&#946;-TRCP1</sup> complex in the presence of active Plk2 and dependent upon its phosphodegron. Constructs expressing full-length myc-SPAR (WT or <italic>AA</italic>) were co-expressed in HEK293T cells with active (WT) or catalytically inactive Plk2 (D201A). Before lysis and immunoprecipitation with 9E10-agarose, cells were treated with proteasome inhibitor MG-132 (25 &#956;<sc>m</sc>) for 5 h. Proteins bound to 9E10-agarose were analyzed via immunoblotting using Myc antibodies and antibodies that recognized endogenous &#946;-TRCP1 and Cul1. Myc-SPAR-C3, a fragment of SPAR that does not contain the phosphodegron served as a negative control, and myc-Cdc25A, a known target of SCF<sup>&#946;-TRCP1</sup>, served as a positive control. <italic>G</italic>, phosphodegron-dependent degradation of SPAR by Plk2 and &#946;-TRCP. Myc-SPARWT and myc-SPAR<sup>AA</sup> abundance was compared by immunoblotting with the indicated antibodies in HEK293T cells in the absence and presence of pCMV-HA-Plk2 in the background of empty vector or &#946;-TRCP&#916;F.</p>
###xml 9 2696 9 2644 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>A candidate</bold>&#946;<bold>-TRCP phosphodegron in SPAR.</bold><italic>A</italic>, schematic representation of SPAR domains and SPAR fragments: actin-binding domains (<italic>Act1</italic> and <italic>Act2</italic>), RapGAP, PDZ, and guanylate kinase binding (<italic>GKBD</italic>) domain. The candidate DSGIDT phosphodegron motif (residues 1304-1309) identified in the Act2 domain of SPAR closely resembles the consensus &#946;-TRCP phosphodegron (<italic>inset</italic>). Boundaries of generated C-terminal fragments of SPAR are depicted; C-1, C-2, and Act2 fragments contain the putative phosphodegron motif, whereas C-3 does not. <italic>B</italic> and <italic>C</italic>, SPAR fragments spanning the &#946;-TRCP phosphodegron bind to &#946;-TRCP. HEK293T cells were transfected with vectors expressing SPAR fragments C-1, C-2, C-3 (<italic>B</italic>) or Act2 (<italic>C</italic>) (0.6 &#956;g) either alone or with pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g). In addition, pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g) and <sup>DN</sup>Cul1 (2 &#956;g) were co-transfected as indicated. After 24 h, cell extracts were used for GSH-Sepharose pulldown assays, and proteins were immunoblotted with Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic> and <italic>E</italic>, phosphodegron-dependent binding to &#946;-TRCP. Constructs expressing point mutations (S1305A, T1309A) in full-length SPAR (<italic>E</italic>) and the Act2 fragment (<italic>D</italic>) (myc-SPAR<sup>AA</sup> or myc-Act2<sup>AA</sup>, 0.6 &#956;g) were transfected into HEK293T cells along with pCMV-HA-Plk2<sup>WT/D201A</sup> (0.6 &#956;g), pCMV-<sup>DN</sup>Cul1 (2 &#956;g), and pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g) as indicated. Cell lysates were incubated with GSH-Sepharose and immunoblotted with Myc antibodies. Crude extracts were resolved to control for input. Wild type constructs expressing myc-SPAR and myc-Act2 were used for comparison as a positive control for interaction with GST-&#946;-TRCP. <italic>F</italic>, SPAR associates with endogenous SCF<sup>&#946;-TRCP1</sup> complex in the presence of active Plk2 and dependent upon its phosphodegron. Constructs expressing full-length myc-SPAR (WT or <italic>AA</italic>) were co-expressed in HEK293T cells with active (WT) or catalytically inactive Plk2 (D201A). Before lysis and immunoprecipitation with 9E10-agarose, cells were treated with proteasome inhibitor MG-132 (25 &#956;<sc>m</sc>) for 5 h. Proteins bound to 9E10-agarose were analyzed via immunoblotting using Myc antibodies and antibodies that recognized endogenous &#946;-TRCP1 and Cul1. Myc-SPAR-C3, a fragment of SPAR that does not contain the phosphodegron served as a negative control, and myc-Cdc25A, a known target of SCF<sup>&#946;-TRCP1</sup>, served as a positive control. <italic>G</italic>, phosphodegron-dependent degradation of SPAR by Plk2 and &#946;-TRCP. Myc-SPARWT and myc-SPAR<sup>AA</sup> abundance was compared by immunoblotting with the indicated antibodies in HEK293T cells in the absence and presence of pCMV-HA-Plk2 in the background of empty vector or &#946;-TRCP&#916;F.</p></caption>
###xml 2696 2696 2644 2644 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0460854240004"/>
###xml 0 2696 0 2644 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="42"><bold>A candidate</bold>&#946;<bold>-TRCP phosphodegron in SPAR.</bold><italic>A</italic>, schematic representation of SPAR domains and SPAR fragments: actin-binding domains (<italic>Act1</italic> and <italic>Act2</italic>), RapGAP, PDZ, and guanylate kinase binding (<italic>GKBD</italic>) domain. The candidate DSGIDT phosphodegron motif (residues 1304-1309) identified in the Act2 domain of SPAR closely resembles the consensus &#946;-TRCP phosphodegron (<italic>inset</italic>). Boundaries of generated C-terminal fragments of SPAR are depicted; C-1, C-2, and Act2 fragments contain the putative phosphodegron motif, whereas C-3 does not. <italic>B</italic> and <italic>C</italic>, SPAR fragments spanning the &#946;-TRCP phosphodegron bind to &#946;-TRCP. HEK293T cells were transfected with vectors expressing SPAR fragments C-1, C-2, C-3 (<italic>B</italic>) or Act2 (<italic>C</italic>) (0.6 &#956;g) either alone or with pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g). In addition, pCMV-HA-Plk2<sup>WT/K108M</sup> (0.6 &#956;g) and <sup>DN</sup>Cul1 (2 &#956;g) were co-transfected as indicated. After 24 h, cell extracts were used for GSH-Sepharose pulldown assays, and proteins were immunoblotted with Myc antibodies. Crude lysates were blotted as an input control. <italic>D</italic> and <italic>E</italic>, phosphodegron-dependent binding to &#946;-TRCP. Constructs expressing point mutations (S1305A, T1309A) in full-length SPAR (<italic>E</italic>) and the Act2 fragment (<italic>D</italic>) (myc-SPAR<sup>AA</sup> or myc-Act2<sup>AA</sup>, 0.6 &#956;g) were transfected into HEK293T cells along with pCMV-HA-Plk2<sup>WT/D201A</sup> (0.6 &#956;g), pCMV-<sup>DN</sup>Cul1 (2 &#956;g), and pCMV-GST or pCMV-GST-&#946;-TRCP (0.6 &#956;g) as indicated. Cell lysates were incubated with GSH-Sepharose and immunoblotted with Myc antibodies. Crude extracts were resolved to control for input. Wild type constructs expressing myc-SPAR and myc-Act2 were used for comparison as a positive control for interaction with GST-&#946;-TRCP. <italic>F</italic>, SPAR associates with endogenous SCF<sup>&#946;-TRCP1</sup> complex in the presence of active Plk2 and dependent upon its phosphodegron. Constructs expressing full-length myc-SPAR (WT or <italic>AA</italic>) were co-expressed in HEK293T cells with active (WT) or catalytically inactive Plk2 (D201A). Before lysis and immunoprecipitation with 9E10-agarose, cells were treated with proteasome inhibitor MG-132 (25 &#956;<sc>m</sc>) for 5 h. Proteins bound to 9E10-agarose were analyzed via immunoblotting using Myc antibodies and antibodies that recognized endogenous &#946;-TRCP1 and Cul1. Myc-SPAR-C3, a fragment of SPAR that does not contain the phosphodegron served as a negative control, and myc-Cdc25A, a known target of SCF<sup>&#946;-TRCP1</sup>, served as a positive control. <italic>G</italic>, phosphodegron-dependent degradation of SPAR by Plk2 and &#946;-TRCP. Myc-SPARWT and myc-SPAR<sup>AA</sup> abundance was compared by immunoblotting with the indicated antibodies in HEK293T cells in the absence and presence of pCMV-HA-Plk2 in the background of empty vector or &#946;-TRCP&#916;F.</p></caption><graphic xlink:href="zbc0460854240004"/></fig>
FIGURE 4.A candidatebeta-TRCP phosphodegron in SPAR.A, schematic representation of SPAR domains and SPAR fragments: actin-binding domains (Act1 and Act2), RapGAP, PDZ, and guanylate kinase binding (GKBD) domain. The candidate DSGIDT phosphodegron motif (residues 1304-1309) identified in the Act2 domain of SPAR closely resembles the consensus beta-TRCP phosphodegron (inset). Boundaries of generated C-terminal fragments of SPAR are depicted; C-1, C-2, and Act2 fragments contain the putative phosphodegron motif, whereas C-3 does not. B and C, SPAR fragments spanning the beta-TRCP phosphodegron bind to beta-TRCP. HEK293T cells were transfected with vectors expressing SPAR fragments C-1, C-2, C-3 (B) or Act2 (C) (0.6 mug) either alone or with pCMV-GST or pCMV-GST-beta-TRCP (0.6 mug). In addition, pCMV-HA-Plk2WT/K108M (0.6 mug) and DNCul1 (2 mug) were co-transfected as indicated. After 24 h, cell extracts were used for GSH-Sepharose pulldown assays, and proteins were immunoblotted with Myc antibodies. Crude lysates were blotted as an input control. D and E, phosphodegron-dependent binding to beta-TRCP. Constructs expressing point mutations (S1305A, T1309A) in full-length SPAR (E) and the Act2 fragment (D) (myc-SPARAA or myc-Act2AA, 0.6 mug) were transfected into HEK293T cells along with pCMV-HA-Plk2WT/D201A (0.6 mug), pCMV-DNCul1 (2 mug), and pCMV-GST or pCMV-GST-beta-TRCP (0.6 mug) as indicated. Cell lysates were incubated with GSH-Sepharose and immunoblotted with Myc antibodies. Crude extracts were resolved to control for input. Wild type constructs expressing myc-SPAR and myc-Act2 were used for comparison as a positive control for interaction with GST-beta-TRCP. F, SPAR associates with endogenous SCFbeta-TRCP1 complex in the presence of active Plk2 and dependent upon its phosphodegron. Constructs expressing full-length myc-SPAR (WT or AA) were co-expressed in HEK293T cells with active (WT) or catalytically inactive Plk2 (D201A). Before lysis and immunoprecipitation with 9E10-agarose, cells were treated with proteasome inhibitor MG-132 (25 mum) for 5 h. Proteins bound to 9E10-agarose were analyzed via immunoblotting using Myc antibodies and antibodies that recognized endogenous beta-TRCP1 and Cul1. Myc-SPAR-C3, a fragment of SPAR that does not contain the phosphodegron served as a negative control, and myc-Cdc25A, a known target of SCFbeta-TRCP1, served as a positive control. G, phosphodegron-dependent degradation of SPAR by Plk2 and beta-TRCP. Myc-SPARWT and myc-SPARAA abundance was compared by immunoblotting with the indicated antibodies in HEK293T cells in the absence and presence of pCMV-HA-Plk2 in the background of empty vector or beta-TRCPDeltaF.
###end p 41
###begin p 42
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A candidate</bold>
###xml 15 43 12 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP phosphodegron in SPAR.</bold>
###xml 43 44 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 130 134 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Act1</italic>
###xml 139 143 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Act2</italic>
###xml 189 193 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GKBD</italic>
###xml 360 365 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 528 529 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 534 535 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 693 694 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 705 706 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 806 814 789 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/K108M</sup>
###xml 829 831 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1050 1051 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1056 1057 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1181 1182 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1207 1208 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1219 1221 1197 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1233 1235 1211 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1305 1313 1282 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WT/D201A</sup>
###xml 1330 1332 1306 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 1679 1680 1647 1648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1717 1727 1685 1692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP1</sup>
###xml 1855 1857 1820 1822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 2065 2066 2029 2030 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 2364 2374 2325 2332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP1</sup>
###xml 2406 2407 2364 2365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 2499 2501 2454 2456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
A candidatebeta-TRCP phosphodegron in SPAR.A, schematic representation of SPAR domains and SPAR fragments: actin-binding domains (Act1 and Act2), RapGAP, PDZ, and guanylate kinase binding (GKBD) domain. The candidate DSGIDT phosphodegron motif (residues 1304-1309) identified in the Act2 domain of SPAR closely resembles the consensus beta-TRCP phosphodegron (inset). Boundaries of generated C-terminal fragments of SPAR are depicted; C-1, C-2, and Act2 fragments contain the putative phosphodegron motif, whereas C-3 does not. B and C, SPAR fragments spanning the beta-TRCP phosphodegron bind to beta-TRCP. HEK293T cells were transfected with vectors expressing SPAR fragments C-1, C-2, C-3 (B) or Act2 (C) (0.6 mug) either alone or with pCMV-GST or pCMV-GST-beta-TRCP (0.6 mug). In addition, pCMV-HA-Plk2WT/K108M (0.6 mug) and DNCul1 (2 mug) were co-transfected as indicated. After 24 h, cell extracts were used for GSH-Sepharose pulldown assays, and proteins were immunoblotted with Myc antibodies. Crude lysates were blotted as an input control. D and E, phosphodegron-dependent binding to beta-TRCP. Constructs expressing point mutations (S1305A, T1309A) in full-length SPAR (E) and the Act2 fragment (D) (myc-SPARAA or myc-Act2AA, 0.6 mug) were transfected into HEK293T cells along with pCMV-HA-Plk2WT/D201A (0.6 mug), pCMV-DNCul1 (2 mug), and pCMV-GST or pCMV-GST-beta-TRCP (0.6 mug) as indicated. Cell lysates were incubated with GSH-Sepharose and immunoblotted with Myc antibodies. Crude extracts were resolved to control for input. Wild type constructs expressing myc-SPAR and myc-Act2 were used for comparison as a positive control for interaction with GST-beta-TRCP. F, SPAR associates with endogenous SCFbeta-TRCP1 complex in the presence of active Plk2 and dependent upon its phosphodegron. Constructs expressing full-length myc-SPAR (WT or AA) were co-expressed in HEK293T cells with active (WT) or catalytically inactive Plk2 (D201A). Before lysis and immunoprecipitation with 9E10-agarose, cells were treated with proteasome inhibitor MG-132 (25 mum) for 5 h. Proteins bound to 9E10-agarose were analyzed via immunoblotting using Myc antibodies and antibodies that recognized endogenous beta-TRCP1 and Cul1. Myc-SPAR-C3, a fragment of SPAR that does not contain the phosphodegron served as a negative control, and myc-Cdc25A, a known target of SCFbeta-TRCP1, served as a positive control. G, phosphodegron-dependent degradation of SPAR by Plk2 and beta-TRCP. Myc-SPARWT and myc-SPARAA abundance was compared by immunoblotting with the indicated antibodies in HEK293T cells in the absence and presence of pCMV-HA-Plk2 in the background of empty vector or beta-TRCPDeltaF.
###end p 42
###begin p 43
###xml 200 201 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 194 201 188 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 402 403 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 396 403 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 405 414 393 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 7-8</italic>
###xml 429 430 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 435 436 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 483 492 471 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
To directly examine whether beta-TRCP is required for SPAR turnover, we performed a cycloheximide-chase experiment in cells expressing myc-SPAR and Plk2 in the presence of shGFP or shbeta-TRCP (Fig. 3D). Myc-SPAR levels persisted after 45-60 min of cycloheximide treatment under conditions of beta-TRCP depletion (shbeta-TRCP) but disappeared after the same time period in control cells (shGFP) (Fig. 3D, lanes 7-8 compared with 3 and 4). Taken together, these data indicate that SCFbeta-TRCP is critical for Plk2-dependent degradation of SPAR in heterologous cells.
###end p 43
###begin p 44
###xml 26 35 26 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 189 190 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 183 190 180 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>E</italic></xref>
###xml 364 371 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 2</italic>
###xml 376 377 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
To explore whether the SCFbeta-TRCP complex promoted ubiquitination of SPAR, we immunoprecipitated myc-SPAR from MG-132-treated HEK293T cells and immunoblotted for modified myc-SPAR (Fig. 3E). Expression of active Plk2 resulted in detection of ubiquitinated SPAR, and the ubiquitination reaction was further driven in cells by ectopic expression of GST-beta-TRCP (lanes 2 and 3). Together, this suggests that the Plk2-dependent turnover of myc-SPAR occurs through ubiquitination of SPAR.
###end p 44
###begin p 45
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plk2-dependent Recognition of SPAR by</italic>
###xml 42 82 39 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP Involves a Canonical Phosphodegron</italic>
###xml 251 255 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GKBD</italic>
###xml 264 265 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 258 265 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 465 466 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 500 501 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 565 566 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 559 566 546 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 662 663 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 656 663 643 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 775 777 759 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 948 949 929 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 942 949 923 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
Plk2-dependent Recognition of SPAR by beta-TRCP Involves a Canonical Phosphodegron-SPAR is a large protein of 1804 amino acids containing two actin binding domains (Act1 and Act2), a RapGAP domain, a PDZ domain, and a guanylate kinase binding domain (GKBD) (Fig. 4A). Within the Act2 domain, we identified a candidate beta-TRCP recognition motif (DSGIDT, residues 1304-1309) based upon the consensus beta-TRCP recognition motif found in many of its targets (DpSGPhiX(pS/T); Phi= hydrophobic residue, X = any residue, pS or pS/T = phosphoserine or threonine) (Fig. 4A). Initially, we surveyed three fragments of SPAR spanning the C terminus (C-1, C-2, C-3, Fig. 4A) for their ability to interact with co-transfected GST-beta-TRCP1 in HEK293T cells in the presence of Plk2 and DNCul1. Fragments C-1 and C-2 (which contain the candidate phosphodegron) bound to GST-beta-TRCP, whereas the C-3 construct lacking the phosphodegron failed to do so (Fig. 4B). N-terminal SPAR fragments that lack the DSGIDT motif also could not bind to beta-TRCP (data not shown).
###end p 45
###begin p 46
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 78 9 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of SPAR degradation in hippocampal neurons through the SCF</bold>
###xml 78 82 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 82 87 79 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 82 96 79 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> complex.</bold>
###xml 96 99 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 204 210 198 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 314 315 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 320 321 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 353 354 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 434 442 421 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 445 451 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 507 517 494 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 557 563 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yellow</italic>
###xml 619 620 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 625 626 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 715 721 702 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 758 759 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 796 803 781 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel D</italic>
###xml 805 806 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 808 809 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 891 892 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 899 900 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 907 917 892 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E, n</italic>
###xml 949 950 934 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 993 996 978 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 998 999 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 1027 9 1012 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><bold>Regulation of SPAR degradation in hippocampal neurons through the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A-C</italic>, dominant negative &#946;-TRCP constructs block Plk2-dependent loss of SPAR in hippocampal neurons. As in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, DIV16 dissociated rat hippocampal neurons were transfected with dominant negative &#946;-TRCP plasmids (<italic>A</italic> and <italic>B</italic>) or control Skp&#916;F plasmid (<italic>C</italic>) and superinfected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions, as in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values represent the mean &#177; S.E. <italic>n</italic> = 25-37 cells for all constructs in <italic>panel D</italic>; <sup>*</sup>, <italic>p</italic> &lt; 0.05 indicates significant difference from theoretical mean of 100%, Student's <italic>t</italic> test (<italic>D</italic>). For <italic>panel E, n</italic> = 19-37 cells (infected only), <italic>n</italic> = 13-28 cells (infected and transfected), <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann Whitney test.</p>
###xml 9 1027 9 1012 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47"><bold>Regulation of SPAR degradation in hippocampal neurons through the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A-C</italic>, dominant negative &#946;-TRCP constructs block Plk2-dependent loss of SPAR in hippocampal neurons. As in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, DIV16 dissociated rat hippocampal neurons were transfected with dominant negative &#946;-TRCP plasmids (<italic>A</italic> and <italic>B</italic>) or control Skp&#916;F plasmid (<italic>C</italic>) and superinfected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions, as in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values represent the mean &#177; S.E. <italic>n</italic> = 25-37 cells for all constructs in <italic>panel D</italic>; <sup>*</sup>, <italic>p</italic> &lt; 0.05 indicates significant difference from theoretical mean of 100%, Student's <italic>t</italic> test (<italic>D</italic>). For <italic>panel E, n</italic> = 19-37 cells (infected only), <italic>n</italic> = 13-28 cells (infected and transfected), <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann Whitney test.</p></caption>
###xml 1027 1027 1012 1012 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0460854240005"/>
###xml 0 1027 0 1012 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="47"><bold>Regulation of SPAR degradation in hippocampal neurons through the SCF</bold><sup>&#946;</sup><bold><sup>-TRCP</sup> complex.</bold><italic>A-C</italic>, dominant negative &#946;-TRCP constructs block Plk2-dependent loss of SPAR in hippocampal neurons. As in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, DIV16 dissociated rat hippocampal neurons were transfected with dominant negative &#946;-TRCP plasmids (<italic>A</italic> and <italic>B</italic>) or control Skp&#916;F plasmid (<italic>C</italic>) and superinfected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (<italic>Sin-Plk2</italic>). <italic>Arrows</italic> point to cells that are both transfected and infected; <italic>arrowheads</italic> point to cells that are infected only. <italic>Yellow</italic> indicates the presence of both SPAR and Plk2 staining. <italic>D</italic> and <italic>E</italic>, quantification of SPAR immunostaining in somatic and proximal dendritic regions, as in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. Values represent the mean &#177; S.E. <italic>n</italic> = 25-37 cells for all constructs in <italic>panel D</italic>; <sup>*</sup>, <italic>p</italic> &lt; 0.05 indicates significant difference from theoretical mean of 100%, Student's <italic>t</italic> test (<italic>D</italic>). For <italic>panel E, n</italic> = 19-37 cells (infected only), <italic>n</italic> = 13-28 cells (infected and transfected), <sup>***</sup>, <italic>p</italic> &lt; 0.001, Mann Whitney test.</p></caption><graphic xlink:href="zbc0460854240005"/></fig>
###xml 230 233 <span type="species:ncbi:10116">rat</span>
###xml 419 432 <span type="species:ncbi:11034">Sindbis virus</span>
FIGURE 5.Regulation of SPAR degradation in hippocampal neurons through the SCFbeta-TRCP complex.A-C, dominant negative beta-TRCP constructs block Plk2-dependent loss of SPAR in hippocampal neurons. As in Fig. 1, DIV16 dissociated rat hippocampal neurons were transfected with dominant negative beta-TRCP plasmids (A and B) or control SkpDeltaF plasmid (C) and superinfected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (Sin-Plk2). Arrows point to cells that are both transfected and infected; arrowheads point to cells that are infected only. Yellow indicates the presence of both SPAR and Plk2 staining. D and E, quantification of SPAR immunostaining in somatic and proximal dendritic regions, as in Fig. 1. Values represent the mean +/- S.E. n = 25-37 cells for all constructs in panel D; *, p < 0.05 indicates significant difference from theoretical mean of 100%, Student's t test (D). For panel E, n = 19-37 cells (infected only), n = 13-28 cells (infected and transfected), ***, p < 0.001, Mann Whitney test.
###end p 46
###begin p 47
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of SPAR degradation in hippocampal neurons through the SCF</bold>
###xml 69 73 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 73 78 70 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 73 87 70 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> complex.</bold>
###xml 87 90 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 195 201 189 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 305 306 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 311 312 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 344 345 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 425 433 412 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sin-Plk2</italic>
###xml 436 442 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 498 508 485 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 548 554 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yellow</italic>
###xml 610 611 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 616 617 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 706 712 693 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 749 750 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 787 794 772 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel D</italic>
###xml 796 797 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 799 800 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 882 883 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 890 891 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 898 908 883 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E, n</italic>
###xml 940 941 925 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 984 987 969 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink">***</sup>
###xml 989 990 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 221 224 <span type="species:ncbi:10116">rat</span>
###xml 410 423 <span type="species:ncbi:11034">Sindbis virus</span>
Regulation of SPAR degradation in hippocampal neurons through the SCFbeta-TRCP complex.A-C, dominant negative beta-TRCP constructs block Plk2-dependent loss of SPAR in hippocampal neurons. As in Fig. 1, DIV16 dissociated rat hippocampal neurons were transfected with dominant negative beta-TRCP plasmids (A and B) or control SkpDeltaF plasmid (C) and superinfected 2 days later with FLAG-tagged Plk2 driven by Sindbis virus (Sin-Plk2). Arrows point to cells that are both transfected and infected; arrowheads point to cells that are infected only. Yellow indicates the presence of both SPAR and Plk2 staining. D and E, quantification of SPAR immunostaining in somatic and proximal dendritic regions, as in Fig. 1. Values represent the mean +/- S.E. n = 25-37 cells for all constructs in panel D; *, p < 0.05 indicates significant difference from theoretical mean of 100%, Student's t test (D). For panel E, n = 19-37 cells (infected only), n = 13-28 cells (infected and transfected), ***, p < 0.001, Mann Whitney test.
###end p 47
###begin p 48
###xml 161 162 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 155 162 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 172 179 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 3</italic>
###xml 184 185 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 191 192 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 197 198 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 290 292 287 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 301 302 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 295 302 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 336 338 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 347 348 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 341 348 338 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 607 608 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 601 608 592 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>F</italic></xref>
###xml 618 625 609 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 2</italic>
###xml 630 631 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 861 870 852 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 886 887 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 880 887 868 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>F</italic></xref>
###xml 889 896 877 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 1</italic>
###xml 901 902 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 1148 1150 1136 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1165 1166 1153 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1159 1166 1147 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>G</italic></xref>
###xml 1168 1177 1156 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 1-4</italic>
###xml 1217 1219 1205 1207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1324 1331 1305 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 4</italic>
###xml 1336 1337 1317 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">8</italic>
###xml 1416 1425 1397 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 1461 1463 1439 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">AA</sup>
###xml 1572 1573 1550 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1566 1573 1544 1551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 1581 1591 1559 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes 1, 2</italic>
###xml 1597 1598 1575 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 1606 1607 1584 1585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1600 1607 1578 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>G</italic></xref>
A fourth fragment of SPAR spanning the Act2 domain was sufficient to interact with beta-TRCP, and its association depended upon expression of active Plk2 (Fig. 4C, compare lanes 3 and 4 with 5 and 6). Mutation of Ser-1305 and Thr-1309 to alanines within the Act2 domain fragment alone (Act2AA) (Fig. 4D) or within full-length SPAR (SPARAA) (Fig. 4E) resulted in greatly diminished binding to beta-TRCP compared with wild type SPAR constructs. Moreover, only in the presence of catalytically active Plk2 was full-length SPAR able to associate with endogenous beta-TRCP and its associated Cul1 protein (Fig. 4F, compare lanes 2 and 3). Importantly, the C-3 fragment of SPAR that does not encompass the phosphodegron as well as full-length SPAR that carries point mutations of Ser-1305 and Thr-1309 did not support interaction with components of the endogenous SCFbeta-TRCP complex (Fig. 4F, lanes 1 and 4). If this DSGIDT motif in SPAR is important for SPAR turnover, then mutation of this candidate phosphodegron should render SPAR resistant to Plk2-mediated turnover. Indeed, Plk2 efficiently promoted degradation of wild type SPAR but not the SPARAA mutant (Fig. 4G, lanes 1-4). Importantly, the accumulation of SPARAA seen in the presence of Plk2 was unchanged by the additional cotransfection of beta-TRCPDeltaF (compare lanes 4 and 8), indicating that the mutation is specifically protecting turnover via the SCFbeta-TRCP pathway. We further noted that SPARAA continued to migrate as multiple bands upon SDS-PAGE analysis of extracts from cells expressing Plk2 (Fig. 4E, input lanes 1, 2, and 4, Fig. 4G). This implies that the mobility shift seen with Plk2 expression does not solely rely on phosphorylation of residues Ser-1305 and Thr-1309.
###end p 48
###begin p 49
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCF</italic>
###xml 3 7 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sup>
###xml 7 12 4 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-TRCP</sup>
###xml 7 59 4 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>-TRCP</sup> Controls SPAR Abundance in Hippocampal Neurons</italic>
###xml 94 103 91 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 227 230 <span type="species:ncbi:10116">rat</span>
###xml 320 323 <span type="species:ncbi:10116">rat</span>
SCFbeta-TRCP Controls SPAR Abundance in Hippocampal Neurons-To investigate the role of the SCFbeta-TRCP complex in post-mitotic neurons of the central nervous system, we first examined whether beta-TRCP is present in the adult rat brain. mRNAs encoding beta-TRCP1, beta-TRCP2, and Cul1 are all present at high levels in rat brain, specifically in the CA1-CA3 regions of the hippocampus, the dentate gyrus, and cerebral cortex (Allen Brain Atlas).
###end p 49
###begin p 50
###xml 12 21 12 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 505 514 490 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 628 634 593 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 861 867 812 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 212 215 <span type="species:ncbi:10116">rat</span>
###xml 778 791 <span type="species:ncbi:11034">Sindbis virus</span>
Does the SCFbeta-TRCP complex regulate turnover of SPAR in neurons? Unlike for the human mRNAs, we have yet to identify an shRNA sequence that can target both beta-TRCP1 and beta-TRCP2 transcripts efficiently in rat neurons. Co-transfection of different shRNAs that individually target beta-TRCP1 and beta-TRCP2 has not yielded satisfactory knockdown of both proteins, possibly due to low efficiency of cotransfection of both shRNA vectors in the same neuron. Therefore, we opted to disrupt endogenous SCFbeta-TRCP function by overexpression of dominant-negative beta-TRCP constructs beta-TRCP1DeltaF or beta-TRCP2DeltaF. As in Fig. 1, DIV16 cultured hippocampal neurons were transfected with either beta-TRCP1DeltaFor beta-TRCP2DeltaF and then super-infected 2 days later with Sindbis virus to drive expression of FLAG-tagged Plk2 and induce SPAR degradation (Fig. 5).
###end p 50
###begin p 51
###xml 210 211 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 204 211 200 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 227 228 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 367 368 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 383 384 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 377 384 366 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 509 510 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 525 526 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 519 526 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 577 586 559 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
Transfection of control dominant-negative Skp2 F-box construct (Skp2DeltaF) in the absence of Plk2 infection had no effect on endogenous SPAR levels relative to nearby untransfected and uninfected cells (Fig. 5C, quantified in D). In contrast, uninfected cells overexpressing beta-TRCP1DeltaF displayed higher levels of SPAR compared with nearby untransfected cells (p < 0.05, Fig. 5D). In neurons overexpressing beta-TRCP2DeltaF, SPAR levels trended upwards, but this did not reach statistical significance (p = 0.11, Fig. 5D). These results suggest that there may be some SCFbeta-TRCP complex-dependent turnover of endogenous SPAR in hippocampal neurons cultured under basal conditions.
###end p 51
###begin p 52
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 123 134 123 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>A-C</italic></xref>
###xml 136 146 136 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 249 250 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 243 250 239 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 293 303 289 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 319 325 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 368 369 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 529 530 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 535 536 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 521 536 503 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>B</italic> and <italic>C</italic></xref>
###xml 552 553 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 642 644 624 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">DN</sup>
###xml 704 710 686 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 755 764 737 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 506 519 <span type="species:ncbi:11034">Sindbis virus</span>
As expected, endogenous SPAR levels were close to undetectable in Plk2-infected neurons that were otherwise untransfected (Fig. 5, A-C, arrowheads, and E) as well as in Plk2-infected cells that had been previously transfected with Skp2DeltaF (Fig. 5C, compare SPAR staining in cells marked by arrowheads (infected) and arrows (transfected and infected); quantified in E). In contrast, cells transfected with beta-TRCP1DeltaF or beta-TRCP2DeltaF showed no reduction in SPAR levels after infection with Plk2 Sindbis virus (Fig. 5, B and C, quantified in E). These results are consistent with disruption of the SCF complex through expression of DNCul1, which also prevented Plk2-dependent loss of SPAR (see Fig. 1), and together they demonstrate that the SCFbeta-TRCP pathway is required for Plk2-induced SPAR degradation in neurons.
###end p 52
###begin p 53
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 126 135 126 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 333 334 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 505 508 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-C</italic>
###xml 688 689 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 694 695 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 753 762 740 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 879 888 863 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
Because changes in SPAR expression can affect spine morphology (5) and synaptic strength (43), we wondered if blocking the SCFbeta-TRCP pathway might also affect these aspects of neuronal function. Infection of DIV16 neurons with Plk2 led to a significant decrease in the size and number of spines, consistent with previous results (5). The additional overexpression of beta-TRCPDeltaF in cells infected with Plk2, however, did not prevent the decrease in size and number of spines (supplemental Fig. S1, A-C). Similarly, blocking beta-TRCP function had no effect on synaptic strength as assessed by recording of miniature excitatory postsynaptic currents (mEPSCs) (supplemental Fig. S1, D and E). These results are perhaps not surprising given that SCFbeta-TRCP is likely to regulate additional synaptic substrates besides SPAR. Although we have clearly established the Plk2-SCFbeta-TRCP-SPAR degradative pathway, its function in neurons remains to be resolved.
###end p 53
###begin title 54
DISCUSSION
###end title 54
###begin p 55
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 473 495 473 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans</italic>
###xml 500 523 500 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster</italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 473 495 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 500 523 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The UPP has received increasing attention in neurobiology as an important regulator of synapse development, synaptic transmission and plasticity, and the dynamic turnover of PSD proteins (27-31). Aberrant UPP function has been implicated in the pathogenesis of certain neurodegenerative disorders, e.g. Parkinson, Alzheimer, Huntington, and prion diseases, and amyotrophic lateral sclerosis (32, 33). To date most E3 substrate pairs in neurobiology have been identified in Caenorhabditis elegans and Drosophila melanogaster (34-42), and relatively little is known about the specific E3s that regulate synaptic proteins in the mammalian brain.
###end p 55
###begin p 56
###xml 63 72 63 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 279 280 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 282 284 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 300 309 297 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 494 496 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 497 499 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 501 503 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 638 640 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
###xml 642 644 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 710 719 693 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
In this study we have uncovered a role for the E3 Ub-ligase SCFbeta-TRCP in the degradation of a key postsynaptic scaffolding protein and enzyme (the RapGAP SPAR) that regulates the morphology of dendritic spines and the strength of synaptic transmission in hippocampal neurons (5, 43). Mammalian SCFbeta-TRCP has been implicated in the ubiquitin-dependent turnover of several cell cycle and other signaling proteins, including IkappaBalpha, beta-catenin, Cdc25A, Emi1, and the Period protein (14-17, 19). Moreover, it has been connected to the differentiation of neural progenitors through its targeting of REST transcription repressor (44, 45). Although we have defined the residues that are critical for SCFbeta-TRCP-mediated degradation of SPAR, it is possible that SPAR degradation is also regulated by additional E3s, possibly in response to other signals and involving different determinants in the SPAR protein.
###end p 56
###begin p 57
###xml 192 193 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 320 322 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 498 502 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 608 610 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 612 614 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 616 618 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 797 806 777 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 816 818 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 819 821 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref55">55</xref>
Previous studies have demonstrated that beta-TRCP interacts with its substrates in a phosphorylation-dependent manner. The majority of beta-TRCP substrates identified to date contain a DpSGPhiXpS sequence (where pS is phosphoserine) that functions as a phosphodegron and directly binds to the WD40 repeats of beta-TRCP (46). A variety of kinases have been implicated in the phosphorylation of beta-TRCP phosphodegrons, and in many cases, multiple kinases collaborate to generate the phosphodegron, e.g. GSK3beta/CKI (for beta-catenin), Chk1 and another unknown kinase (for Cdc25A), and Cdc2/Plk1 (for Emi1) (14, 15, 47). Interestingly, Emi1 is one of several cell cycle regulators, in addition to Wee1, Emi2, and Claspin, that is phosphorylated by Plk family member Plk1 for degradation by the SCFbeta-TRCP complex (47-55). Thus, Plk family members seem to collaborate with beta-TRCP to regulate the degradation of a variety of substrates in different cellular contexts.
###end p 57
###begin p 58
###xml 74 78 71 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1304</sup>
We found that SPAR contains a canonical beta-TRCP phosphodegron sequence (1304DSGIDT) in its Act2 domain. Point mutations in Ser-1305 and Thr-1309 within SPAR inhibited Plk2-dependent SPAR degradation and its binding to beta-TRCP, providing evidence that this sequence functions as a phosphodegron.
###end p 58
###begin p 59
###xml 58 62 58 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1304</sup>
###xml 479 487 476 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 489 490 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 688 689 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 1074 1075 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 1160 1167 1157 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus</italic>
###xml 1293 1295 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref56">56</xref>
###xml 1160 1167 <span type="species:ncbi:8355">Xenopus</span>
###xml 1172 1181 <span type="species:ncbi:7955">zebrafish</span>
Currently, the identity of the kinase that phosphorylates 1304DSGIDT in SPAR is not definitively established. A direct demonstration that Plk2 phosphorylates Ser-1305 and Thr-1309 is currently lacking due, in part, to difficulty in purifying modified full-length SPAR. Thus, further studies are required to definitively correlate that these candidate sites are phosphorylated by Plk2. Nevertheless, because Plk2 promotes the SPAR-beta-TRCP interaction and can phosphorylate SPAR in vitro (6), we favor the idea that Plk2 is the kinase responsible for phosphorylation of Ser-1305 and Thr-1309 in this phosphodegron. Supporting this idea is that Plk2 also binds to the Act2 domain of SPAR (6), so the kinase would be recruited to the vicinity of the phosphodegron. However, we cannot rule out the possibilities that Plk2 activity is required but not sufficient for phosphorylation of Ser-1305 and Thr-1309, that additional kinases are involved, or that additional phosphodegrons exist in SPAR. Plk2 is thus far the only kinase reported to promote SPAR degradation in neurons (6), although it is possible that other kinases could contribute as well. During early Xenopus and zebrafish development, casein kinase Iepsilon has been implicated in the decrease of SPAR protein through Wnt signaling (56).
###end p 59
###begin p 60
###xml 44 45 44 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 163 172 163 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 469 478 463 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 715 724 703 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 851 861 833 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 914 919 890 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar-1</italic>
###xml 1010 1012 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 851 861 <span type="species:ncbi:6239">C. elegans</span>
SPAR levels influence spine shape and size (5, 6), and SPAR degradation is involved in activity-dependent synaptic scaling (43). Our results here show that the SCFbeta-TRCP complex targets SPAR for turnover in response to Plk2 activity. Nevertheless, blocking Plk2-dependent SPAR degradation through overexpression of the dominant-negative beta-TRCP construct did not prevent Plk2-dependent changes in spine morphology. This suggests that the exact role of the Plk2-SCFbeta-TRCP-SPAR pathway in neurons is still unclear. Plk2 may regulate the function or expression of additional proteins besides SPAR that are unaffected by disruption of the beta-TRCP degradation pathway. Similarly, by globally disrupting the SCFbeta-TRCP complex in the neuron, additional beta-TRCP substrates may accumulate that offset the effects of accumulated SPAR protein. In C. elegans, the beta-TRCP ortholog Lin-23 targets beta-catenin/bar-1 for destruction in the ventral nerve cord, leading to altered glutamate receptor density (35).
###end p 60
###begin p 61
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 233 242 233 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 349 351 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 595 596 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 604 605 598 599 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 638 639 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 688 697 682 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-TRCP</sup>
###xml 883 885 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
Endogenous Plk2 expression is induced during periods of elevated neuronal activity and causes degradation of SPAR protein as well as thinning and elongation of spines (6). The accumulation of SPAR in spines upon inhibition of the SCFbeta-TRCP pathway as well as the recent report that proteasomes redistribute into spines with synaptic stimulation (11) is consistent with the possibility that phosphorylation of SPAR by Plk2 leads to local interaction with beta-TRCP and degradation of SPAR at postsynaptic sites. Because SPAR is a large scaffolding protein in the PSD that forms complexes with N-methyl-d-aspartate receptors and PSD-95 (5), regulation of SPAR degradation through the SCFbeta-TRCP complex may be predicted to play a significant role in regulating the composition of proteins in the spine. Given the critical role of the proteasome in turning over many PSD proteins (10), it is likely that additional specific E3s will be identified that regulate synaptic composition.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplemental Data]
###end title 63
###begin p 64
We thank Azad Bonni (Harvard Medical School) for critical reading of the manuscript and Nelly Khidekel (Massachusetts of Technology) for the beta-TRCP2DeltaF construct.
###end p 64
###begin p 65
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 440 448 440 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 217 220 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The abbreviations used are: PSD, postsynaptic density; Ub, ubiquitin; GAP, GTPase activating protein; SPAR, spine-associated Rap GTPase activating protein; Plk2, Polo-like kinase 2; UPP, ubiquitin-proteasome pathway; CMV, cytomegalovirus; HA, hemagglutinin; GFP, green fluorescent protein; SCF, Skp1/Cul1/F-box protein; WT, wild type; RFP, red fluorescent protein; GST, glutathione S-transferase; RNAi, RNA-mediated interference; DIV, days in vitro; shRNA, short hairpin RNA; E3, ubiquitin-protein isopeptide ligase; beta-TRCP, beta-transducin repeat-containing protein.
###end p 65
###begin p 66
D. P. Seeburg, unpublished observation.
###end p 66

